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A B S T R A C T
Background
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and is a leading cause of morbidity and mortality. Screening
for AF in asymptomatic patients has been proposed as a way of reducing the burden of the disease by detecting people who would
benefit from prophylactic anticoagulation therapy prior to the onset of symptoms. However, for screening to be an effective intervention
it must improve the detection of AF and provide benefit for those who are detected earlier as a result of screening.
Objectives
The primary objective of this review was to examine whether screening programmes increase the detection of new cases of AF compared
to routine practice. The secondary objectives were to identify which combination of screening strategy and patient population is most
effective, as well as assessing any safety issues associated with screening, its acceptability within the target population and the costs
involved.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) on The Cochrane Library, MEDLINE (Ovid) and
EMBASE (Ovid) up to March 2012. Other relevant research databases, trials registries and websites were searched up to June 2012.
Reference lists of identified studies were also searched for potentially relevant studies and we contacted corresponding authors for
information about additional published or unpublished studies that may be relevant. No language restrictions were applied.
Selection criteria
Randomised controlled trials, controlled before and after studies and interrupted time series studies comparing screening for AF with
routine practice in people aged 40 years and over were eligible. Two authors (PM, CT or MF) independently selected the trials for
inclusion.
Data collection and analysis
Assessment of risk of bias and data extraction were performed independently by two authors (PM, CT). Odds ratios (OR) and 95%
confidence intervals (CI) were used to present the results for the primary outcome, which is a dichotomous variable. Since only one
included study was identified, no meta-analysis was performed.
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Main results
One cluster randomised controlled trial met the inclusion criteria for this review. This study compared systematic screening (by invitation
to have an electrocardiogram (ECG)) and opportunistic screening (pulse palpation during a general practitioner (GP) consultation for
any reason followed by an ECG if pulse was irregular) to routine practice (normal case finding on the basis of clinical presentation) in
people aged 65 years or older. The risk of bias in the included study was judged to be low.
Both systematic and opportunistic screening of people over the age of 65 years are more effective than routine practice (OR 1.57, 95%
CI 1.08 to 2.26 and OR 1.58, 95% CI 1.10 to 2.29, respectively). The number needed to screen in order to detect one additional case
compared to routine practice was 172 (95% CI 94 to 927) for systematic screening and 167 (95% CI 92 to 806) for opportunistic
screening. Both systematic and opportunistic screening were more effective in men (OR 2.68, 95% CI 1.51 to 4.76 and OR 2.33,
95% CI 1.29 to 4.19, respectively) than in women (OR 0.98, 95% CI 0.59 to 1.62 and OR 1.2, 95% CI 0.74 to 1.93, respectively).
No data on the effectiveness of screening in different ethnic or socioeconomic groups were available. There were insufficient data to
compare the effectiveness of screening programmes in different healthcare settings.
Systematic screening was associated with a better overall uptake rate than opportunistic screening (53% versus 46%) except in the≥ 75
years age group where uptake rates were similar (43% versus 42%). In both screening programmes men were more likely to participate
than women (57% versus 50% in systematic screening, 49% versus 41% in opportunistic screening) and younger people (65 to 74
years) were more likely to participate than people aged 75 years and over (61% versus 43% systematic, 49% versus 42% opportunistic).
No adverse events associated with screening were reported.
The incremental cost per additional case detected by opportunistic screening was GBP 337, compared to GBP 1514 for systematic
screening. All cost estimates were based on data from the single included trial, which was conducted in the UK between 2001 and
2003.
Authors’ conclusions
Systematic and opportunistic screening for AF increase the rate of detection of new cases compared with routine practice. While both
approaches have a comparable effect on the overall AF diagnosis rate, the cost of systematic screening is significantly more than that of
opportunistic screening from the perspective of the health service provider. The lack of studies investigating the effect of screening in
other health systems and younger age groups means that caution needs to be exercised in relation to the transferability of these results
beyond the setting and population in which the included study was conducted.
Additional research is needed to examine the effectiveness of alternative screening strategies and to investigate the effect of the intervention
on the risk of stroke for screened versus non-screened populations.
P L A I N L A N G U A G E S U M M A R Y
Screening people aged over 65 years for atrial fibrillation increases the rate of detection
Atrial fibrillation is a common cardiac arrhythmia that makes the heart beat rapidly and irregularly. This can occur for brief episodes or
may be continuous. Symptoms of the disease include heart palpitations, chest pain, shortness of breath, light-headedness and fatigue.
The condition is rare in those under 40 years but gets more common as people age. Not everyone with atrial fibrillation experiences
symptoms so some people are unaware that they have it, while others may experience mild symptoms that they do not attribute to the
disease. Atrial fibrillation hinders the efficient flow of blood through the heart, resulting in an increased risk of clot formation. If these
clots leave the heart they can block the vessels supplying blood to the brain, causing a stroke. Treatment with anticoagulant medication
is designed to prevent the formation of blood clots and can reduce the risk of stroke by over 60%.
For a screening programme for atrial fibrillation to be worthwhile it needs to increase the rate of detection as well as benefitting those
who are detected with the problem through screening. The aim of this review was to examine the first part of this question, to find
out if screening increases the number of new diagnoses of atrial fibrillation compared with normal practice where people are diagnosed
when they consult a health professional with symptoms or risk factors that would lead to them being tested. It also examined the safety
and rate of uptake of screening, as well as the costs involved.
The review identified one study that met the inclusion criteria. This examined systematic screening, where everyone over 65 years
was offered an electrocardiogram (ECG) test, and opportunistic screening, where those over 65 years had their pulse taken when they
visited their general practitioner (GP) for any reason and were offered an ECG if an irregular pulse was found. Both these screening
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programmes increased the rate of detection of new cases of atrial fibrillation compared to normal practice. Screening appeared to be
more effective in men than women but no information was available about its effectiveness in different ethnic or socioeconomic groups.
Since only one study was found, it was not possible to compare the effectiveness of screening in different settings. Uptake of screening
was higher for systematic screening than for opportunistic screening, and within both interventions the uptake was higher for men and
the 65 to 74 age group compared to people over 75 years. No safety issues or complications were reported. From the point of view of
the health service provider, systematic screening was more costly than opportunistic screening. However, because all of the results are
based on a single study, one needs to be cautious about applying them outside of the setting (UK primary care) and patient population
(aged over 65 years) in which the study was carried out.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Screening versus routine practice for the detection of atrial fibrillation
Patient or population: patients with the detection of atrial fibrillation
Settings:
Intervention: screening
Comparison: routine practice
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Routine practice Screening
Systematic Screening
versus Routine Practice
Number of new diag-
noses
Follow up: 12 months
Study population OR 1.56
(1.08 to 2.24)
9075
(1 study)
⊕⊕⊕©
moderate1
10 per 1000 16 per 1000
(11 to 23)
Moderate
10 per 1000 16 per 1000
(11 to 22)
Opportunistic Screening
versus Routine Practice
Number of new diag-
noses
Follow up: 12 months
Study population OR 1.57
(1.1 to 2.26)
9088
(1 study)
⊕⊕⊕©
moderate1
10 per 1000 16 per 1000
(11 to 23)
Moderate
10 per 1000 16 per 1000
(11 to 22)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Given the nature of the intervention it was not possible to blind the participants in this study. No deliberate attempt to conceal allocation
was made but failure to do this is not judged to introduce a risk of selective enrolment.
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B A C K G R O U N D
Screening for atrial fibrillation (AF) in asymptomatic patients has
been proposed as a way of reducing the burden of stroke by detect-
ing people who would benefit from prophylactic anticoagulation
prior to the onset of symptoms of the arrhythmia (Harris 2012).
The idea of screening for this condition is not new (for example
Baxter 1998; Sudlow 1998; Wheeldon 1998), however there is re-
newed interest in the topic given the continued high incidence of
stroke in many countries along with data showing that significant
room for improvement remains in the identification and manage-
ment of AF (Lip 2012). The overall evaluation of the benefits of
a systematic screening programme for atrial fibrillation requires
consideration of the probability of adverse health outcomes in the
absence of screening, the degree to which screening identifies all
people who would suffer these adverse health outcomes and the
magnitude of incremental health benefits of earlier versus later
treatment resulting from screening (Harris 2011). This review is
related to the second of these three considerations; does systematic
screening for AF in adults identify people with previously undiag-
nosed AF more effectively than routine practice?
Description of the condition
AF is the most common arrhythmia in clinical practice and is a
leading cause of morbidity and mortality (Fuster 2006). The con-
dition is characterised by predominantly uncoordinated atrial ac-
tivation with consequent deterioration of atrial mechanical func-
tion. Some cases can be asymptomatic, while other people with
AF may experience palpitations, chest pain, dizziness or, in severe
cases, loss of consciousness (NCCCC 2006). The ‘3 P’ system
classifies AF according to the frequency of the attacks and whether
they are self terminating or require pharmacological or medical
cardioversion (Levy 2003). Using this classification system, AF in
people who experience two ormore episodes that terminate within
seven days is classified as paroxysmal AF. If a person has more than
one attack that lasts longer than seven days it is termed persistent
AF. Finally, if the AF episode lasts for more than a year or cannot
be terminated by cardioversion it is classified as permanent AF.
The frequency of reoccurrence in paroxysmal AF can increase over
time or may degenerate into persistent or eventually permanent
AF (NCCCC 2006). Persistent AF as a result of an underlying
heart condition can often be returned to normal sinus rhythm
by treating the underlying cause. In addition to classifying AF in
terms of the frequency of symptoms, different types of AF may
be distinguished by the presence or absence of other underlying
heart problems. Lone AF generally applies to individuals under
60 years of age without clinical or echocardiographic evidence of
cardiopulmonary disease, including hypertension. Valvular and
non-valvular AF describe whether associated disorders of the heart
valves, including rheumatic mitral valve disease, a prosthetic heart
valve, or mitral valve repair, are present or absent (Fuster 2006).
In studies that included epidemiological data from the United
Stated (US) and Australia, the prevalence of AF in the general
population was estimated to be between 0.4% and 1% (Feinberg
1995; Go 2001). The prevalence of AF increases with age (Fuster
2006), rising from 2.3% in those over 40 years of age to around
8% in those over 80 years (Wolf 1991; Furberg 1994; Feinberg
1995). Prevalence estimates vary however, especially in the older
age group, with some European epidemiological studies reporting
a prevalence of approximately 17% in those aged ≥ 85 years (
Heeringa 2006; Bilato 2009). The median age of AF patients is 75
years and 70% are between 65 and 85 years old (Feinberg 1995).
Using data from the US and Canada, the corresponding incidence
of AF for those under 40 years is less than 0.1% per year, rising to
1.5% in women and 2% in men older than 80 years (Wolf 1987;
Krahn 1995; Psaty 1997).
Of particular importance in terms of systematic screening is the
prevalence and risk profile of people with AF who have not been
diagnosed, either because they are asymptomatic (’silent AF’) or
their symptoms remain unrecognised. It is estimated that one third
of people with AF have no obvious symptoms (Furberg 1994;
Savelieva 2000). However, assessing the prevalence of this type of
AF is challenging since episodes of the arrhythmia may be brief,
completely asymptomatic and difficult to detect (Savelieva 2000),
and people experiencing mild symptoms may attribute them to
other causes. In the absence of systematic screening, asymptomatic
AF is diagnosed incidentally through routine physical examina-
tions, pre-operative assessments or after complications such as
stroke or heart failure have occurred. The Framingham Study
found that among patients who had a stroke due to AF, the ar-
rhythmia was first diagnosed in 24% of cases (Wolf 1983). A later
report by the same group showed that 18% of participants who
experienced stroke related to AF were newly diagnosed following
admission, and another 4.4% were diagnosed with paroxysmal AF
within 14 days (Lin 1995). It has been suggested that silent AF
may also be associated with silent cerebral infarcts; in one study
(Cullinane 1998) silent embolic signals were detected by transcra-
nial Doppler in 13% of patients with symptomatic AF and 16%
of those with asymptomatic AF. The relationship between asymp-
tomatic AF or AF with few symptoms and the development of
cardiomyopathy was investigated by Grogan et al (Grogan 1992),
who found a significant improvement in left ventricular function
after restoration of sinus rhythm or adequate ventricular rate re-
sponse during AF. In this study of people who had little or no
awareness of their arrhythmia and only sought medical attention
when symptoms of heart failure developed, it was concluded that
asymptomatic and undiagnosed AF may cause, rather than result
from, severe left ventricular dysfunction. The idea that the risk
profile and subsequent clinical management of symptomatic AF
may also extend to asymptomatic AF is consistent with the find-
ings of other studies which have shown that the type of AF (sus-
tained versus paroxysmal) does not impact on risk of stroke or non-
central nervous system (non-CNS) embolism (Hohnloser 2007)
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and that continuous anticoagulation is warranted in all patients
with atrial fibrillation and risk factors for stroke even when sinus
rhythm appears to be restored and maintained (Wyse 2002).
AF is associated with an increased risk of stroke, congestive heart
failure, cognitive dysfunction, reduced quality of life and all cause
mortality (Ott 1997; Benjamin 1998; Stewart 2002). The mortal-
ity rate among people with AF is about double that among those
with normal sinus rhythm and is linked to the severity of the un-
derlying heart disease (Kannel 1983; Flegel 1987; Krahn 1995).
AF contributes to an increased risk of stroke due to haemodynamic
instability caused by irregular fast heartbeat and thromboembolic
complications. For non-valvular AF populations the two-year age-
adjusted incidence of stroke and thromboembolism is increased
five-fold (Wolf 1991). This risk increases with age; the Framing-
ham Study estimated that the annual risk of stroke attributable
to AF in people aged 50 to 59 years was 1.5%, which rose to
23.5% in people aged 80 to 89 years (Wolf 1991). In addition,
stroke due to AF is almost twice as likely to be fatal compared to
stroke in the absence of AF and results in greater functional im-
pairment for those who survive (Lin 1996). CHADS2, and more
recently CHA2DS2-VASC, are clinical prediction rules that have
been used to estimate the risk of stroke in AF and to recommend
anticoagulation therapy based on risk factors such as age, sex and
clinical history. A CHADS score of ≥ 1, corresponding to an an-
nual risk of stroke of 2.8%, indicates that anticoagulation therapy
should be considered (ESC 2010).
The last 20 years have seen a 66% increase in hospitalisations due
to AF, and AF currently accounts for one third of all hospitali-
sations for cardiac rhythm disturbances (Freiberg 1997; Stewart
2001; Wattigney 2003; Fuster 2006). This is due to population
ageing, the rising prevalence of chronic heart disease and advances
in diagnosis. The condition is also associated with high economic
costs to the individual and society. It is estimated that the annual
cost per patient is approximately EUR 3000, while the total soci-
etal cost in the EU is about EUR 13.5 billion (Fuster 2006).
Description of the intervention
Systematic screening programmes for AF differ from routine prac-
tice by offering tests for AF to a wider range of people then those
who present in routine consultations with symptoms, risk factors
or other indications for AF testing. A systematic approach would
define which test to use in conjunction with which screening strat-
egy in order to increase the diagnosis of AF in the community,
including patients with asymptomatic AF or those who are symp-
tomatic but remain undiagnosed. A screening strategy of oppor-
tunistic pulse taking or ECG recording during a routine consul-
tation is treated as a type of systematic screening strategy if all
patients who are offered the test are identified a priori and the in-
tervention is offered regardless of the reason for the consultation.
The current gold standard test to detect AF is a 12-lead ECG
interpreted by a cardiologist (Hobbs 2005). Other tests that can
be used may involve alternative types of ECG (limb lead, three-
lead, five-lead) read by a general practitioner (GP) in combina-
tion with preliminary pulse palpation carried out by a physician
or nurse. Pulse palpation, however, is not conclusive on its own
(Cooke 2006). Due to the intermittent nature of paroxysmal AF,
either frequent repeated electrocardiograms (where the arrhythmia
is present at the time of the test) or continuous ambulatory ECG
monitoring tests are sometimes required (Go 2001). These diag-
nostic tests can be employed using a range of screening strategies,
including opportunistic, targeted and population based screening.
Opportunistic screening usually involves pulse palpation during
the course of a routinemedical consultation, with recourse to ECG
if an irregular pulse is detected. Targeted or structured screening
involves the identification of certain groups considered to be at
higher risk of having AF or groups that can otherwise be singled
out for screening. Finally, there is the option of conducting pop-
ulation based screening programmes where screening is offered to
everyone in a particular population who has not previously been
diagnosed with AF.
Screening programmes can differ in the population screened, the
testing regime used and the health professionals carrying out the
tests and interpreting the results. Some interventions described
previously have involved either one or two step processes, de-
pending on whether ECG was used on its own or in conjunc-
tion with pulse palpation, with the population tending to be those
over 65 years of age. Nurse led pulse palpation, ECG recording
by physicians or ECG technicians and interpreted by physicians
and cardiologists have been reported. For example, Wheeldon et
al (Wheeldon 1998) used a one step strategy, inviting all peo-
ple aged over 65 years within a primary care practice for a single
12-lead ECG performed by an ECG technician and interpreted
by a hospital cardiologist. In another study, Morgan and Mant
(Morgan 2002) randomised patients over 65 years to either nurse
led pulse palpation or opportunistic pulse palpation prompted by
a reminder flag on their medical records, with irregular pulse find-
ings in both arms being confirmed using a lead II rhythm strip
interpreted by a general physician.
The costs associated with systematic screening have been exam-
ined in a number of published studies and are dependent on the
screening strategy used and the health system within which they
are implemented. Hobbs et al (Hobbs 2005) calculated UK costs
for opportunistic screening, systematic screening in high risk pop-
ulations and population based systematic screening (all in those
over 65 years) and found that the incremental cost per additional
case detected compared to no screening was lowest for opportunis-
tic screening (GBP 337, GBP 3520 and GBP 1514, respectively).
Maeda et al (Maeda 2004) calculated the incremental cost of an-
nual ECG screening for patients between 65 and 85 years of age
compared to no screening in Japan to be approximately USD 125
for men and USD 150 for women.
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How the intervention might work
Systematic screening for AF in general adult populations could po-
tentially increase diagnosis rates by identifying people with asymp-
tomatic AF as well as those who are symptomatic but remain
undiagnosed because of failure to attribute symptoms to the ar-
rhythmia and to seek medical attention. A systematic screening
programme creates a broader window for diagnosis compared to
routine practice since it tests people prior to the occurrence of
symptoms or complications. Therefore, such an intervention may
result in greater numbers of people being diagnosed, or receiving
an earlier diagnosis compared with routine practice, as the time
period within which AF is occurring is likely to be correlated with
diagnosis, and AF can begin prior to the advent of symptoms
or complications, or both (Wolf 1983; Cullinane 1998; Savelieva
2000). The effectiveness of the intervention depends on a number
of factors, including the prevalence of undiagnosed AF, choice of
screening strategy and its acceptability to the patient population,
as well as the costs associated with the intervention.
Given the relatively high prevalence of AF in older populations,
and the increased morbidity and mortality associated with it, a
screening programme that increased the rate of detection of AF
has the potential to reduce the incidence of adverse cardiovascular
events in this high risk population. Earlier diagnosis of AF will
help identify those who would benefit from oral antiplatelet or
anticoagulant prophylaxis, calculated to reduce the relative risk
of stroke in patients with AF by approximately 20% and 60%,
respectively (Hart 2007; ESC 2010). However, even if systematic
screening is shown to increase the rate of detection of AF, it will
still be necessary to evaluate the magnitude of the overall clinical
benefits and harms in order to avoid bias associated with screening
(for example over-diagnosis, length-time bias) and to prevent in-
accurate conclusions being drawn about the effectiveness of treat-
ment in patients who are identified through systematic screening
programmes. Also, since the cardiovascular risk profile of screen
detected people may be lower than that of those who present with
symptoms and co-morbidities caused by AF, the balance of risk
(adverse event) and benefit (stroke avoided) associated with pro-
phylactic treatment would likely be altered.
It has also been pointed out previously (Hobbs 2005) that screen-
ing for AF meets many of the Wilson-Jungner (Wilson Jungner
1968) criteria for screening for disease. The condition is an impor-
tant health problem and there is an accepted treatment for people
following diagnosis and a suitable test or examination exists. One
of the secondary aims of this review is to examine the evidence for
some of the other screening criteria, such as the acceptability of the
test to the population and the cost of case-finding, which should
be economically balanced in relation to possible expenditure on
medical care as a whole.
Why it is important to do this review
AF is under-diagnosed and under-treated, especially in the elderly
(Hobbs 2005; ESC 2010; Ogilvie 2010). The condition lends it-
self to screening since testing is considered to be relatively inexpen-
sive and efficient in terms of the follow up required. The primary
objective of systematic screening is to reduce the risk of disease
within a population through early detection, so that patients can
receive treatment to improve their clinical outcomes. This review
addresses the first part of that objective, namely the extent towhich
screening can be reasonably assumed to increase detection. Given
the existing evidence in relation to the clinical benefit to be gained
from treatment of AF, including asymptomatic AF, a systematic
screening programme would seem to be an attractive option if it
could be shown to increase the rate of detection compared to rou-
tine practice. The size of this benefit is unclear since data specifi-
cally relating to screen detected patients are unavailable, however
randomised controlled trial (RCT) data on the primary prevention
of ischaemic stroke in AF patients using a vitamin K antagonist
compared to controls indicates a relative risk reduction of 67%
(ESC 2010).
This review does not examine the evidence in regard to the degree
of benefit, in terms of cardiovascular events avoided or increased
quality of life, that can result from earlier diagnosis. Nor does it
specifically seek to find out if those identified through systematic
screening programmes are more or less likely to eventually suf-
fer the adverse consequences associated with the arrhythmia than
those diagnosed through routine practice. While these issues may
be examined in further research, it is important to know first of
all whether or not the use of systematic screening succeeds in its
primary objective of increasing the detection rate of AF in the gen-
eral population. If the introduction of systematic screening pro-
grammes fail to increase the detection rate for AF, there can be no
subsequent change in health benefits and the other criteria need
not be examined. On the other hand, if there is an increase in the
rate of detection then subsequent treatment of these patients may
reduce their individual risk of experiencing adverse cardiovascu-
lar events and reduce the overall burden of the disease within the
health systems that introduce such a programme.
O B J E C T I V E S
This review aims to answer the following questions.
1. Does systematic screening increase the
detection of AF compared to routine practice?
The primary objective of the review was to investigate whether
there is evidence of a difference in the detection of new cases of
AF between systematic screening and routine practice. Clinical
outcomes associated with having received an earlier diagnosis and
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subsequent treatment are not within the scope of this review. Ear-
lier detection is assumed to result in improved outcomes within
the screened population, as it is generally accepted that effective
treatments exist to manage symptoms and reduce the risk of stroke
for those with a diagnosis of AF.
2. Which combination of screening population,
strategy and test is the most effective at
detecting AF compared to routine practice?
Evidence for the effectiveness of different types of screening pro-
grammes was compared to find out which method detects AF
more effectively. For screening programmes that were shown to be
more effective than routine practice, the magnitude of the bene-
fit in terms of overall numbers of new AF cases detected and the
number needed to screen in order to detect one additional case
compared to routine practice were calculated.
3. What are the potential safety issues and
adverse events associated with individual
screening programmes?
In any systematic screening programme for AF, a large number of
people will be tested in order to identify a small number who have
the arrhythmia. Therefore, any harms associated with screening
will affect a much larger proportion of the screened population
than the proportion who will experience the benefits associated
with being diagnosed. This review assesses the safety and adverse
events associated with individual screening programmes. The po-
tential harms depend on the type of screening involved but can
include complications associated with testing, anxiety generated
by the screening process, as well as inconvenience associated with
investigation and follow up. Potential harms occurring after di-
agnosis are not assessed in this review; these may include adverse
events related to treatment, such as haemorrhagic stroke, unnec-
essary treatments as a result of over-diagnosis, or adverse effects of
labelling or early diagnosis.
4. How acceptable is the intervention to the
target population?
One of the most important factors affecting the effectiveness of
a screening programme is the participation of the target group.
If a screening programme is unacceptable to the target popula-
tion, uptake is likely to be low (Jepson 2000). Evidence in regard
to the acceptability of individual screening programmes to both
the healthcare professionals and the screening population involved
was evaluated. Factors that may affect acceptability include antici-
pated or actual pain, discomfort or embarrassment, or if a positive
diagnosis is followed up by an intervention or treatment that is
considered to be unacceptable (Jepson 2000). Costs incurred by
the patient over the course of the screening process are included
in the acceptability analysis on the basis that higher costs deter pa-
tients from participating in screening programmes (Frazier 1990).
5. What are the costs associated with
systematic screening for AF?
Direct costs from the perspective of the healthcare provider were
assessed in order to provide data on the practicalities of imple-
menting individual programmes, in terms of likely resource allo-
cation, compared to routine practice. Since an overall analysis of
the magnitude of the health benefits and harms will not be carried
out, the cost data reported were limited to the incremental costs
of screening compared no screening and the costs per additional
case identified, where such information was available.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All randomised controlled trials (RCT) and cluster randomised
controlled trials (cluster-RCT) comparing systematic screening to
routine practice were eligible for inclusion, irrespective of language
or publication status.
Quasi-experimental study designs (controlled before and after
(CBA) studies and interrupted time series (ITS) studies) compar-
ing systematic screening to routine practice were eligible for in-
clusion, subject to the criteria stated in the Cochrane Handbook
for Systematic Reviews of Interventions (Box 6.3.a) (Higgins 2011)
and criteria developed by the Cochrane Effective Practice and Or-
ganisation of Care (EPOC) Group (EPOC 2011). ITS studies
were only to be included if the numbers of people in the pre and
post-intervention populations were reported. Due to the nature
of the intervention, it was considered appropriate to include non-
randomised study designs and analyse these separately. Large scale
population based screening programmes could potentially be eval-
uated in well designed CBA and ITS studies with a high degree
of external validity in circumstances where randomisation is not
feasible.
Case series, cohort studies, studies that use historical controls or
cross-sectional studies were excluded.
Results from randomised studieswere reported separately to results
from quasi-experimental studies, where applicable.
Studies comparing more than one systematic screening pro-
gramme were eligible for inclusion as long as there was a control
arm of routine care included in the study.
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Types of participants
Men and women over the age of 40 years. Epidemiological data
indicate that AF is extremely uncommon prior to age 40 years,
with the two-year AF incidence in the absence of rheumatic heart
disease estimated at 0.04% for men and 0% for women aged 30
to 39 years (Wolf 1987). Therefore, younger participants were ex-
cluded due to the extremely low incidence of AF in this popu-
lation, which would render systematic screening unfeasible, and
to avoid inclusion of studies involving specific patient groups (for
example paediatric or elite athletes) where the aetiology, diagnosis
and subsequent clinical management of AFmay differ from age-re-
lated onset of AF. Studies that included patients with implantable
pacemakers or defibrillators or a previous diagnosis of AF in the
control and intervention group were eligible for inclusion as long
as these patients were excluded from the final number of newly
diagnosed cases of AF reported.
Types of interventions
Studies eligible for inclusion compared population based, targeted
or opportunistic screening programmes to no screening, where
the control or pre-intervention (for ITS studies) group relied on
routine practice for the diagnosis of AF over the relevant time
period. The method of detecting AF in the intervention group
could consist of single or multi-step processes but the diagnosis
needed to be ultimately confirmed using 12-lead or continuous
ambulatory ECG interpreted by a GP, specialist or suitably trained
ECG technician or nurse in both the intervention and control (or
pre-intervention) groups. Interventions that used pulse palpation
alone or other types of ECG reading to confirm a diagnosis of AF
were excluded.
Routine practice (control group) was defined as diagnoses made
during routine care, either incidentally or following presentation
with indications for AF testing, that were subsequently confirmed
using 12-lead or continuous ambulatory ECG interpreted by a
GP, specialist or suitably trained ECG technician or nurse. In ad-
dition, there had to be a clear mechanism for recording the num-
ber of new diagnoses of AF made over the relevant study period
in this group. Opportunistic screening, where all members of the
intervention group had their pulse recorded during the course of a
routine consultation for any reason, was differentiated from rou-
tine practice where AF diagnoses were made following presenta-
tion with symptoms of an arrhythmia, or incidentally through
other examinations, but where specific AF testing for all patients
was not mandated. Studies that only used an alternative systematic
screening strategy, instead of routine practice, as the control were
not eligible for inclusion.
Types of outcome measures
Primary outcomes
The primary outcome being investigated was the difference in the
detection of new cases of AF associated with systematic screen-
ing compared to routine practice, for individual screening pro-
grammes identified as being eligible for inclusion in the review and
where a diagnosis of AF was defined as a positive reading using a
12-lead or continuous ambulatory ECG interpreted by a specialist,
physician or suitably trained ECG technician or nurse. This infor-
mation was used to calculate the overall difference in the numbers
of AF cases detected compared to routine practice, as well as the
number needed to screen (NNS) in order to detect one additional
case of AF within the population. If studies describing multiple
different systematic screening programmes had been identified,
then AF detection rates for each were to be ranked according to
their effectiveness when compared to routine practice. This was
only to be calculated using data from studies that provided a clear
denominator. In the case of RCT and CBA studies, this would be
the numbers of people in the intervention or control groups, mak-
ing sure that patients with a prior AF diagnosis were excluded. For
ITS studies, data were only to be included if a clear denominator
(number of patients in post-interrupt group) was reported.
Secondary outcomes
1. Acceptability of systematic screening programmes within
the target population
Acceptability of screening was examined in three ways: the level
of uptake achieved, feedback elicited from the participants and
health professionals involved, and a description of any direct costs
associated with screening that were borne by the person to whom
the screening programme was offered.
The level of uptake of a systematic screening programme was de-
fined as the percentage of the screening population that partic-
ipated in the full screening programme. For screening strategies
that involve more than one stage (for example pulse palpation fol-
lowed by ECG), uptake was defined as those who completed both
stages. Data relating to the level of uptake among subgroups of
the overall population were also reported for individual screening
programmes.
Issues in regard to the acceptability of the intervention to the
patient or health professional, or both, may depend on the type of
screening programme involved. They were eligible for inclusion if
based on primary data collected through the use of questionnaires,
interviews or other means of eliciting the experience and opinions
of the participants or health professionals involved. A narrative
summary of the issues affecting the acceptability of different types
of screening programmes was provided.
Costs incurred by the patient taking part in the screening pro-
gramme were described as part of the analysis of the acceptability
of the intervention to the patient, with higher costs being assumed
to be less acceptable than lower or no costs.
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2. Adverse events associated with systematic screening
programmes
The rate and severity of complications or adverse events associated
with ECG or other forms of AF testing were recorded.
Psychological distress, change in quality of life and impact on
well-being were included if these outcomes were measured using
a validated scale. Adverse events related to treatment following a
diagnosis of AF were excluded.
3. Analysis of the costs associated with systematic screening
programmes for AF
Only direct costs from the perspective of the healthcare provider
were included in the analysis of this outcome. Where possible, a
description of the operational and training costs associated with
screening was provided along with the incremental cost of screen-
ing and cost per additional case detected compared with a policy
of no screening.
4. Changes to the known prevalence of AF
Using data from patients included in cluster-RCTs and CBA stud-
ies, an estimate of the prevalence of AF within the screening pop-
ulation was calculated. Data from studies that do not provide a
clear denominator, which may be the case with some ITS studies
especially, were not included in the calculation of this outcome.
Data from RCTs, CBA and ITS studies that did not report the
numbers of patients who had a prior diagnosis of AF were not
included in the calculation of this outcome.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (2012, Issue 3 of 12) on The Cochrane Library,
MEDLINE (Ovid) (1948 to February week 4 2012) and EM-
BASE and EMBASE Classic (Ovid) (1947 to Week 11 2012) for
RCTs (Appendix 1), CBA and ITS studies (Appendix 2) on 22
March 2012.
The Cochrane RCT filter (sensitivity maximising) was applied to
MEDLINE and terms used by The Cochrane Collaboration to
limit a search to RCTs in EMBASE were applied to EMBASE
(Lefebvre 2011). The EPOCmethods filter was applied to MED-
LINE and EMBASE to limit the searches for the other included
study designs.
Searching other resources
The following databases, trials registries and websites were also
searched for relevant studies up to 1st June 2012:
CINAHL (via EBSCO), ClinicalTrials.gov, ISRCTN Registry,
Stroke Trials Directory, the World Health Organization (WHO)
International Clinical
Trials Registry Platform (ICTRP) (Clinical Trials Registry of the
University Medical Center Freiburg, EU Clinical Trials Register,
German Clinical Trials Register, Iranian Registry of Controlled
Trials, Japanese NIPH Clinical Trials Registry, UMIN-
CTR (Japan), Nederlands Trial Register, Pan African Clinical
Trials Registry, Sri Lanka Clinical Trials Registry, Australia New
Zealand Clinical Trials Registry, Brazilian Clinical
Trials Registry, Chinese Clinical Trials Registry, Korean Clinical
Research Information Service, Clinical Trials Registry India) and
the websites of Eurostroke (European Stroke Conference), EHRA
and ACC (see Appendix 3 for the search terms used in each of
these resources).
Reference lists of all included papers were searched to identify po-
tentially relevant articles. Where required, we contacted lead au-
thors and investigators for information about additional published
or unpublished studies that may be relevant.
Nodate or language restrictionswere applied to any of the searches.
Data collection and analysis
Selection of studies
Preliminary screening of all returned results was carried out by a
single author (PM) to eliminate studies whichwere clearly not rele-
vant. Assessment of eligibility of studies and identification of mul-
tiple reports from single studies were carried out independently
by two authors (PM and either CT or MF). Disagreements were
resolved by discussion or, if necessary, by a third author (either CT
or MF).
Data extraction and management
Data extractionwas performed independently by two authors (PM
and CT). Disagreements were resolved by discussion or, if neces-
sary, by a third author (MF).
The following data were extracted from included studies.
1) All relevant data pertaining to the study characteristics and the
primary and secondary outcomes of interest.
This included the study setting, number of centres, funding, pa-
tients characteristics, screening method and AF test used, number
of patients in each arm, AF cases detected, patient uptake, fac-
tors affecting participation, quality of life data related to screen-
ing, other adverse events or complications, prevalence of AF in the
study population, and cost data related to screening.
2) All data required in order to perform risk of bias assessment.
This included study design, allocation method, blinding proce-
dures if any, patient withdrawals, reporting of all outcomes, and
risk of contamination. Studies were examined for other potential
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threats to the validity of their findings that were specific to the
particular trial design and clinical setting.
Assessment of risk of bias in included studies
Two authors (PM and CT) independently assessed the risk of bias
in included studies in accordance with the guidelines stated in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011). This was determined using the Collaboration’s risk of bias
tool included in section 8.5 of the handbook, which categorises
studies as either high risk of bias, low risk of bias or unclear risk
of bias.
Risk of bias in ITS and CBA studies was to be assessed using meth-
ods developed by the Cochrane Effective Practice and Organisa-
tion of Care (EPOC) Group (Suggested risk of bias criteria for
EPOC reviews). CBA risk of bias criteria include analysis of the
methods used for participant selection, study performance, AF de-
tection and reporting of results. ITS risk of bias criteria include
analysis of whether the intervention was independent of other
changes, if the shape of the intervention effect was pre-specified
and if the intervention was unlikely to affect data collection.
This review was not subject to some types of bias associated with
screening (for example lead-time bias) since the primary outcome
was a difference in the rate of detection as opposed to survival or
time to event data. Biases associated with screening studies that
could result in incorrect conclusions being drawn are length time
and over-diagnosis bias. Length time is a form of selection bias
where patients with slowly progressing AF are more likely to be
identified by screening than people for whom the onset of symp-
toms and associated adverse cardiovascular events are more acute.
This is because of the longer time period within which people
are asymptomatic but would test positive for AF, making them
more likely to be picked up by screening. Similar to lead-time bias,
this can make it appear that cases discovered through screening
fare better than those that present with symptoms, but in reality
the difference is not due to screening but because screening dis-
proportionately identifies slowly progressing AF. Despite the fact
that no time-to-event data were included, there is a risk to this
review from length-time bias arising from overestimation of the
benefit of screening by assuming that all identified cases will de-
rive the same benefit from anticoagulation prophylaxis to reduce
the risk of stroke when in fact the patients who would benefit the
most (that is those with more severe, rapidly progressing AF) are
least likely to be identified through screening. This is also the case
for paroxysmal AF, which is likely to be more difficult to detect
through screening than is persistent or permanent AF. However,
available evidence suggests that stroke risk in these two groups are
similar (Friberg 2010). A similar situation exists with regard to
over-diagnosis bias, where the implementation of a screening pro-
gramme may result in asymptomatic AF patients being diagnosed
and treated when in the absence of a screening programme they
may never have become symptomatic or suffered a stroke as a re-
sult of the arrhythmia. However, these biases do not introduce sys-
tematic errors into the primary outcome of concern in this review
(AF diagnosis rate), rather they may lead to over-interpretation of
the clinical gains associated with increasing the detection of AF
through systematic screening.
Studies were assessed for other sources of bias that may be relevant
to specific methods used in the performance of the research. For
instance some screening programmes involve a two step process
to test for AF, with manual pulse palpation being performed ini-
tially followed by an ECG if an irregular pulse is found. Since the
accuracy of pulse palpation is affected by the skill and experience
of the medical practitioner (Hobbs 2005), there is the potential
for an intervention bias related to variations in the proficiency of
different health professionals performing the test, which would
influence the results of the study. However as this is not a review
of diagnostic test accuracy, as long as the intervention specifies
the type of reader used it will be possible to avoid inappropriate
comparisons across studies. Other types of bias that were to be
considered, depending on the type of study involved, included
compliance bias if the intervention or control group involved self
initiated testing by the patient, which can lead to outcomes being
driven by how compliant the participants are rather than the ef-
fectiveness of the screening intervention (Fletcher 2005). Studies
were assessed on an individual basis for other potential sources of
bias.
Measures of treatment effect
The effect of systematic screening was measured by the difference
in the number of cases of AF detected between the control and
intervention groups divided by the number of cases in each group.
Differences were expressed as the overall magnitude of the differ-
ence in the AF detection rate between the intervention and con-
trol or pre-intervention groups as well as the number needed to
screen (NNS) in order to detect one additional case of AF within
the population.
Pooled analysis of treatment effect was to be carried out using
standard meta-analytic techniques, provided enough study data
were obtained and taking account of heterogeneity between stud-
ies. Fixed-effect model meta-analysis would be performed initially,
with the option of using random-effects model meta-analysis if a
moderate or high degree of heterogeneity was observed between
studies. As a summary measure of effectiveness, odds ratios (OR)
with 95% confidence intervals (CI) were calculated for dichoto-
mous variables.
Results from studies describing different screening interventions
were not pooled and the results from randomised and non-ran-
domised studies were to be reported separately.
Unit of analysis issues
Cluster-randomised trials were assessed in order to ensure that
appropriate analysis was carried out to address cluster effects and
to avoid overestimating the significance of differences. In cluster-
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randomised studies where the analysis was carried out as if the
randomisation was performed on the individuals rather than the
clusters, efforts were to be made to obtain the data needed to cor-
rect for this, as described in section 16.3.4 of the Cochrane Hand-
book for Systematic Reviews of Interventions (Higgins 2011). For
controlled trials that compared more than one screening method
the meta-analysis of each method was to be performed separately
to avoid counting the control group twice.
Dealing with missing data
Lead investigators or corresponding authors were contacted for
any missing data or for additional clarification.
Assessment of heterogeneity
An assessment of the heterogeneity of included studies was to be
performed if sufficient data were available to perform ameta-anal-
ysis. I2 values above 75% are considered to have exceeded the level
of heterogeneity appropriate for drawing meaningful conclusions
from pooled data. Chi2 tests for heterogeneity were also planned
to be performed and data were to be considered heterogeneous if P
< 0.10. Significant statistical heterogeneity was to be investigated,
along with the clinical heterogeneity of the populations across in-
cluded studies.
Assessment of reporting biases
Studies were assessed to check if all relevant outcomes in the study
protocol were reported in the final results, per the risk of bias
heading ’selective outcome reporting’. Any outcomes specified in
the methods that were omitted from the results were taken as
evidence that outcomes were selectively reported. In the event of
evidence of selective reporting authors were to be contacted to
enquire if the results were reported elsewhere (that is published in
another paper or otherwise available). Asymmetry of the funnel
plot based on the data for the primary outcome would be taken
as an indication of publication bias.
Data synthesis
A narrative of the results of included studies is provided along with
information on their risk of bias. A meta-analysis of similar stud-
ies to produce a combined estimate of the effect was planned if
multiple studies were identified, subject to acceptable levels of sta-
tistical and clinical heterogeneity. Differences between the results
of fixed-effect and random-effects model meta-analysis would re-
quire re-examination of the clinical and methodological diversity
of the pooled studies before making a judgment on which would
be the most appropriate statistical model to use. In the event that
insufficient data were available to perform a meta-analysis, effect
sizes and confidence intervals of each outcome from the included
study were to be reported individually.
Subgroup analysis and investigation of heterogeneity
Subgroup analysis was to be performed on the following groups
subject to the availability of sufficient data.
1. Over 65 years of age.
2. Aged 65 to 75 years versus > 75 years.
3. Men versus women.
4. Different ethnic groups, if reported.
5. Different socioeconomic groups, if reported.
6. Community versus specialist setting.
Subgroups were identified a priori based on a plausible rationale
supported, where possible, by published literature. The number
of subgroups was kept to a minimum and priority was given to
subgroups that are of specific interest to the potential implemen-
tation of a systematic screening programme.
The primary subgroup examined was the effectiveness of the in-
tervention in the over 65 years age group. The comparator for this
subgroup was people over 65 years for whom no screening pro-
gramme was introduced. This group is of relevance for two rea-
sons. Firstly, one of the features of an ideal screening programme
in primary care is that there is a sufficiently high prevalence of
the disease in the screened population to justify screening (Goroll
1995). The prevalence of AF increases substantially with age (Wolf
1991; Feinberg 1995; Go 2001). The median age of AF patients
is 75 years and 70% are between 65 and 85 years old. Therefore
a screening programme in this group is likely to be more effective
given the higher baseline prevalence of the condition compared to
the overall population included in the review. The second reason
why the over 65 age group is important is because they are a recog-
nised group within most public health systems, thus providing an
opportunity to capitalise on existing structures to effectively target
a public health initiative such as a screening programme.
Given the increasing prevalence of AF with age, it may be logical
to assume that the older the age group targeted by the screening
programme the more effective it will be. To investigate this issue,
a separate subgroup analysis of people aged 65 to 75 years versus
those > 75 years was conducted in order to compare the effec-
tiveness of systematic screening in an older population within the
group for which screening is most likely to be implemented in
practice (that is all over 65 years).
The effectiveness of systematic screening inmenversuswomenwas
also examined in the subgroup analysis since there are a number of
reasons to presume that gender could influence the effectiveness
of a screening programme for AF. Men are 1.5 times more likely
than women to develop the disease (Benjamin 1994) and this may
make screening in menmore effective given the higher underlying
prevalence. In addition to this, there are factors relating to the
potential differences in the uptake of any screening programme in
men and women that could impact on outcomes. The direction
of this effect is uncertain, however. It has been reported that men
are more reluctant than women to contact their GPs and other
healthcare services (Peate 2004). In another study in theUS (CDC
2001) it was found that despite excluding pregnancy-related visits,
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women were 33%more likely than men to visit a doctor, although
this difference decreased with age. However, others have reported (
Wardle 2005; Friedemann-Sanchez 2007) thatmen aremore likely
to attend colorectal cancer screening than women. Since the rate
of uptake of screening is such an important factor in determining
the success of a screening programme (Barratt 2002; Parkin 2008)
it is worthwhile to separately investigate the differences in reported
outcomes for men and women.
Apart from gender, ethnicity and social deprivation are the two
main factors found to influence population based cancer screen-
ing programmes in the UK (Weller 2009). This review had also
planned to include subgroup analysis of the effectiveness of screen-
ing in different ethnic and socioeconomic groups, if these were
reported, in order to provide useful data that could be relevant to
readers of the review. There are risks involved since the practice
of including data on outcomes only if they are reported can lead
to the introduction of bias as significant results are more likely to
get published than non-significant results. However it was antici-
pated that, due to the established importance of these factors, the
reporting of data on ethnicity and socioeconomic status would
more than likely be carried out for large population based screen-
ing programmes where it is appropriate and is unlikely to be re-
ported in studies where the participant population or screening
approach is incompatible with such an analysis. Despite this, it
had been planned to clearly explain the limitations of any available
data and the caveats associated with subgroup interpretation in
the reporting of the review had it been possible to conduct this
analysis.
The final subgroup that was to be examined relates to the setting
within which the screening programme was conducted. It is possi-
ble that studies of screening strategies carried out within the com-
munity or in primary care could have been identified along with
studies based in specialist settings like hospitals or other secondary
care facilities. Given the importance of the setting to any consider-
ation of how amajor screening programme could be implemented
within a health system, it was considered important to provide
an analysis of any differences in the reported outcomes associated
with the setting. The setting could affect how well a screening
programme performs in a number of ways. The acceptability of
the clinical settings where systematic screening takes place to the
person to whom the test is offered can affect the rate of uptake and
settings within the community, such as GP or public health nurse
led programmes, may be more acceptable, and therefore more ef-
fective, for people who are used to receiving care in these settings.
As with the ethnicity and socioeconomic subgroups, this subgroup
analysis was only be performed if it was considered appropriate to
do so after consideration of the studies included in the review.
Sensitivity analysis
Depending on the studies obtained from the systematic search, a
sensitivity analysis was to be conducted to calculate the effect of
risk of bias within studies on effect size by calculating the effect of
excluding or including studies with a higher risk of bias.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
One (cluster) randomised controlled trial (cluster-RCT) met the
inclusion criteria (Hobbs 2005). No eligible controlled before and
after (CBA) studies or interrupted time series (ITS) studies were
identified. Two potentially relevant studies that are currently on-
going were also identified (NCT01593553; NCT01291953).
Results of the search
We identified 19,936 citations during the search. After removal of
duplicates and screening out irrelevant studies, 130 citations were
reviewed independently by two authors (PMandCTorMF). This
produced four citations that met the inclusion criteria (Swancutt
2004; Hobbs 2005; Fitzmaurice 2007; Mant 2007), all of which
were based on the same study (Hobbs 2005). See Figure 1 formore
details. Seven authors were contacted during the review process to
enquire if they had conducted additional research in this area since
the publication of their last article, or if they knew of other studies
that may be eligible for inclusion. Despite a high rate of response
(5/7) no further studies were identified that met the inclusion
criteria.
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Figure 1. Study flow diagram.
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Included studies
The single study that met the inclusion criteria for this review was
a cluster-randomised trial comparing screening of those aged 65
years or over to routine practice in the primary care setting in the
UK (Hobbs 2005). A total of 25 general practices with comput-
erised record keeping systems were randomised to either the con-
trol or intervention groups. Randomisation was stratified accord-
ing to practice size and level of deprivation (Townsend score). All
practices within the intervention group received educational ma-
terials highlighting the importance of AF detection and the range
of treatment options available. Healthcare professionals within
these practices were encouraged to consider opportunistic pulse
taking during routine consultation. In total, 10,000 patients aged
65 years or older were randomly selected from the intervention
practices and allocated equally between two different screening
interventions embedded within the intervention arm. These were
systematic screening, where patients were invited by letter to at-
tend an ECG screening clinic, or opportunistic screening, where
patients’ GP records were flagged to prompt the GP to check the
pulse whenever that patient next attended the practice for any rea-
son. Health professionals in control practices received no training;
5000 patients aged 65 years or older were randomly selected from
this group for follow up as a comparator group receiving routine
care.
Excluded studies
Fifteen studies examining screening for AF did not meet the
inclusion criteria for this review (Baxter 1998; Sudlow 1998;
Wheeldon 1998; Munschauer 1999; Somerville 2000; Ho 2004;
Morgan 2002; Maeda 2004; Hoefman 2005; Wright 2007;
DeRuijter 2008; Johnson 2010; Marek 2011; Claes 2012;
ACTRN12612000406808). The reasons for their exclusion are
described in the Characteristics of excluded studies section.
Risk of bias in included studies
Since only one study met the inclusion criteria, this review is lim-
ited to summarising risk of bias for that study across outcomes,
with particular reference to the primary outcome of differences in
the rate of detection of AF. A summary of the risk of bias assess-
ment is shown in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
Allocation
The randomisation methods used to allocate patients in the in-
cluded study resulted in a low risk of bias since all centres were ran-
domised at the same time, and the intervention and control groups
were not known at the point of randomisation. Within the treat-
ment group, patients were selected using computer generated ran-
dom numbers and the lists were stratified on the basis of numbers
of patients with an existing diagnosis of AF, which resulted in each
arm having a comparable chance of detecting known, unknown or
suspected AF. There was no deliberate concealment of allocation
to the trial arms but the clusters (GP practices) were identified and
recruited before randomisation was conducted, so allocation was
concealed from the people providing permission for the cluster to
be included in the trial. Similarly, patients in the intervention arm
were identified and randomly allocated into two groups before it
was known to anyone involved in the trial which group would be
allocated to which treatment (opportunistic or systematic). How-
ever, since there was no deliberate attempt to conceal allocation it
is unclear to what extent a risk of selection bias might have arisen
from practices in the intervention arm knowing they were in the
intervention arm and not the control arm prior to the recruitment
of participants. See the Characteristics of included studies table
for more information.
A separate issue is the potential for self selection bias inherent
in screening studies in which patients decide whether or not to
undergo testing. However, given the randomisation methods that
were used and the intention-to-treat analysis performed the risk
of bias associated with this is considered to be low.
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Blinding
Given the nature of the intervention it was not possible to blind
the participants in the included study. In the systematic screening
arm patients were invited to attend an ECG clinic. One of the
factors contributing to the outcome of the intervention was the
rate of uptake of this invitation, which was a decision that had to
be made by individual patients who were provided with adequate
information to make an informed decision. In the opportunistic
screening arm the records of patients were flagged to prompt clin-
icians to offer to palpate the pulse of patients who presented in the
GP practice for any reason. In this arm, patients also needed to be
informed about the intervention and to decide whether or not to
participate. Therefore blinding of patients and GPs as a method
of reducing the likelihood of performance bias was neither achiev-
able or desirable given the intervention. See the Characteristics of
included studies table for more information.
Detection bias was minimised by blinding the two consultant
cardiologists who read the 12-lead ECG about whether the ECG
was from patients who had received an invitation for screening (n
= 2357) or were referred following the detection of an irregular
pulse (n = 238). All ECG tracings were taken by practice nurses
who were probably not blinded to which treatment arm individual
patients were in.
Incomplete outcome data
There was a significant difference in the numbers of patients ex-
cluded by GPs from the systematic and opportunistic arms of the
trial following randomisation. Five hundred patients (10.1%) in
the systematic arm and 195 patients (4%) in the opportunistic
arm had either died, moved away from the practice area, or were
terminally ill or otherwise unsuitable for screening. The risk of
bias associated with this was low, however, since the same criteria
were used to exclude patients in both arms of the intervention and
98% of the withdrawals from the systematic group were due to
patients having died (246 patients) or moved away (245 patients).
An intention-to-treat analysis was used to calculate differences in
the rate of detection of new cases of AF between the different
arms, which used the number of patients in each arm prior to
these withdrawals. Only patients with a pre-existing diagnosis of
AF (7.2%) and patients whose notes were missing (0.6%) were
excluded from the calculation. See the Characteristics of included
studies table for more information.
The notes of all patients within each group were searched at the
end of the study to identify all those who had been diagnosed
with AF over the course of the trial, including those in the inter-
vention groups that had been diagnosed outside of the screening
programme. These diagnoses were included in the analysis of the
primary outcome.
Selective reporting
There was no suggestion of selective reporting in the included
study. All outcomes specified in the trial protocol (Swancutt 2004)
were reported.
Other potential sources of bias
There was an unclear risk of recruitment bias emanating from the
fact that after initial randomisation, lists of patients were given to
GPs to exclude patients who were unsuitable for screening, and
these patients were replaced from a back-up list that had been
generated as part of the original randomisation process. No data
were provided on the numbers from each group who were replaced
at this stage. GPs were instructed to remove people who had died,
moved away, or were terminally ill. Significant differences in the
numbers excluded from each arm may have indicated differences
in the way these criteria were applied by practice GPs across the
two groups, potentially introducing bias. Data from the second
round of exclusions, which was performed immediately prior to
screening, resulted in the removal of 10% of people from the
systematic arm compared to 4% from the opportunistic arm (see
Incomplete outcome data (attrition bias) section above).
Effects of interventions
See: Summary of findings for the main comparison Screening
versus routine practice for the detection of atrial fibrillation;
Summary of findings 2 Systematic screening compared to
opportunistic screening for the detection of atrial fibrillation
For the primary outcome of detection of new cases of AF, results
from the single included study showed that both systematic and
opportunistic screening of people over the age of 65 years for AF
in primary care was more effective than routine practice (OR 1.57,
95% CI 1.08 to 2.26; Analysis 1.1 and OR 1.58, 95% CI 1.10 to
2.29; Analysis 1.2, respectively). There was no significant differ-
ence between systematic and opportunistic screening in terms of
the number of new cases detected (OR 0.99, 95%CI 0.72 to 1.37;
Analysis 2.1). The number needed to screen in order to detect one
additional case compared to routine practice was 172 (95% CI
94 to 927) for systematic screening and 167 (95% CI 92 to 806)
for opportunistic screening. When gender subgroups were anal-
ysed the results indicated that both systematic and opportunistic
screening were more effective in men (OR 2.68, 95% CI 1.51 to
4.76 and OR 2.33, 95% CI 1.29 to 4.19, respectively) than in
women (OR 0.98, 95% CI 0.59 to 1.62 and OR 1.2, 95% CI
0.74 to 1.93, respectively), see Analysis 1.3 and Analysis 1.5. The
difference between the gender subgroups was statistically signifi-
cant for systematic screening (Chi2 = 6.64, P = 0.01; I2 = 84.9%)
but not for opportunistic screening (Chi2 = 2.95, P = 0.09; I2 =
66.1%). Subgroup analysis by age (65 to 74 years, 75 +) failed
to show significant differences in the detection of new cases of
AF between participants in these two age ranges, see Analysis 1.4
and Analysis 1.6. See Table 1 for the numbers of new cases of AF
diagnosed in each group and by gender and age group. No data
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were reported on different ethnic groups. No association between
socioeconomic status and the effectiveness of systematic or oppor-
tunistic screening was reported.
The acceptability of the screening intervention was measured by
the rate of uptake of screening, feedback from participants and
health professionals, as well as the cost associated with screening
from the point of view of the patient. For systematic screening an
invitation was considered accepted if the patient attended an ECG
screening clinic following the receipt of the letter. For opportunis-
tic screening a patient was considered to have participated in the
programme if they agreed to have their pulse taken opportunisti-
cally during a routine consultation and subsequently accepted an
offer of an ECG if an irregular pulse was found. This differed from
the analysis carried out within the included study, which consid-
ered uptake on the basis of those who agreed to have their pulse
taken, even if they declined to have an ECG if an irregular pulse
was found. The rationale for taking a different approach in this
review was that since ECG confirmation was required to make a
diagnosis, patients for whom this was indicated who did not pro-
ceed to have an ECG could not be said to have taken up the offer
of screening since they had not completed the full two stage pro-
cess. Uptake results are shown in Table 2. Systematic screening was
associated with a greater overall rate of uptake than opportunistic
screening, with a higher rate of uptake of systematic screening be-
ing seen in both men and women. This trend was also observed
in the 65 to 74 years age group, but for those aged over 75 years
the uptake rates for both interventions were similar. Overall men
were more likely to participate in screening than women, and peo-
ple from the younger age group (65 to 74 years) were more likely
to participate than those aged 75 years and over. A questionnaire
concerning the acceptability of screening was administered to all
patients undergoing an ECGwithin the intervention arm: 95% of
those who completed this felt that screening was important (1810/
1897); 17% (324/1897) felt that they didn’t know what was in-
volved; and 4% (70/1897) felt it wasn’t convenient. Mean costs
incurred by patients undergoing ECG were GBP 3.13 (95% CI
2.97 to 3.29, range GBP 0.65 to 14.53).
No specific adverse events associated with screening were reported.
Anxiety levels and quality of life were measured at baseline and
at the end of the study using the six-item Spielberger state anxi-
ety inventory and the five-item EQ-5D. A total of 750 question-
naires were distributed to patients in the intervention arm prior to
screening. Six hundred and twenty were returned: 311 from op-
portunistic patients (55 not completed) and 309 from systematic
patients (72 not completed). No significant difference was found
between the two intervention arms at baseline for anxiety (z = -
0.392, P = 0.695) or quality of life (z = -0.334, P = 0.739). A
total of 777 post-screening questionnaires were distributed and
630 were returned, 535 of which were completed: 479 of these
completed the six-item Spielberger state anxiety questions, and
520 competed the five-item EQ-5D questions. No significant dif-
ference was found between the two intervention arms at the end
of the study for anxiety (z = -1.699, P = 0.089) or quality of life
(z = -1.166, P = 0.244). End of study anxiety scores for screen-
positive and screen-negative patients were significantly different
(F (1268) = 4.883, P = 0.028). Patients diagnosed with AF had a
higher anxiety score (38.12, 95% CI 35.89 to 40.35 versus 34.61,
95% CI 32.41 to 36.81) and a lower quality of life score (0.66,
95% CI 0.59 to 0.70 versus 0.73, 95% CI 0.68 to 0.77).
An economic analysis carried out as part of the single included
study found that when costs were examined from the perspec-
tive of a national health service provider (National Health Service
(NHS) in this case) the incremental cost of the estimated 28 ad-
ditional cases detected using opportunistic screening compared to
no screening was GBP 9429 (95% CI 8938 to 9920), giving an
incremental cost per additional case detected of GBP 337. The in-
cremental cost of the estimated 27 additional cases detected using
systematic screening compared to no screening was GBP 40,882
(95% CI 39,790 to 41,974), giving an incremental cost per addi-
tional case detected of GBP 1514. All cost estimates were based
on the trial data, and the trial was conducted in the UK between
2001 and 2003.
AF prevalence results from the included study are presented in
Table 3. This table shows the baseline and 12-month prevalence
of AF within the study population in the control and intervention
arms, with a breakdown of prevalence by gender and age group
(65 to 74, 75 to 84, ≥ 85 years).
There was insufficient data to compare the effectiveness of screen-
ing programmes in different healthcare settings
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Systematic screening compared to opportunistic screening for the detection of atrial fibrillation
Patient or population: patients with the detection of atrial fibrillation
Settings:
Intervention: systematic screening
Comparison: opportunistic screening
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Opportunistic screening Systematic screening
Systematic versus Op-
portunistic Screening
Number of new diag-
noses
Follow up: 12 months
Study population OR 0.99
(0.72 to 1.36)
9137
(1 study)
⊕⊕⊕©
moderate1
16 per 1000 16 per 1000
(12 to 22)
Moderate
16 per 1000 16 per 1000
(12 to 22)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; OR: Odds ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Given the nature of the intervention it was not possible to blind the participants in this study. No deliberate attempt to conceal allocation
was made but failure to do this is not judged to introduce a risk of selective enrolment.2
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D I S C U S S I O N
Summary of main results
Only one study met the eligibility criteria for this review (Hobbs
2005). No studies examining screening in populations under
65 years were identified. Two ongoing studies were identified
that are likely to be of relevance to this review in the future
(NCT01593553; NCT01291953). Based on the results of one
included study, this review found that both systematic and op-
portunistic screening increase the rate of detection of AF in those
people aged 65 years and over compared with routine practice.
There was no significant difference in the relative effectiveness of
the two interventions, with approximately 170 patients needing
to be screened in both groups in order to detect one additional
case. Uptake rates were higher for systematic screening than for
opportunistic screening. Given the additional resources needed to
support population based systematic screening, the overall cost of
this intervention is considerably more than that of opportunistic
screening.
Overall completeness and applicability of
evidence
The single identified study provides evidence on the effectiveness
of screening for AF in people aged over 65 years, the acceptabil-
ity of this intervention in the target population, and the costs as-
sociated with the intervention within a publicly funded primary
care setting. However there is a lack of studies examining other
potential screening strategies, younger populations and different
healthcare settings.
Since the acceptability of the intervention is a key factor in its ef-
fectiveness, differences in regard to participation rates, a patient’s
perception of screening, and direct costs to the patient in different
settings means that caution needs to be exercised in relation to the
transferability of the results. The uptake rate in the overall study
population for opportunistic screening was calculated based on
the numbers of patients who agreed to have their pulse taken and
to have an ECG if an irregular pulse was found; 34% of those that
were found to have an irregular pulse declined an ECG and were
therefore not considered to have been opportunistically screened
since they did not complete the intervention. In the group who
did not consent to an ECG, 46% (56/122) already had a diag-
nosis of AF. When only those without a baseline diagnosis of AF
are used to calculate uptake the percentage of patients who are
discovered to have an irregular pulse but decline an ECG is 27%.
The reasons for such a high dropout rate between irregular pulse
finding and ECG are unknown. If the uptake rate is calculated
solely on the basis of a patient consenting to having their pulse
taken opportunistically during a routine consultation, then the
uptake rate increases to 69%.While low levels of uptake and com-
pletion of screening are a cause for concern, the uptake rate of
the included study is high when compared with an earlier study
within the same health system comparing systematic screening (via
invitation to attend nurse led pulse palpation) to opportunistic
screening (Morgan 2002) that recorded an uptake rate of 29% in
the opportunistic arm based on those who presented for any rea-
son and consented to have their pulse taken regardless of whether
or not an ECG was subsequently used to confirm the diagnosis.
Hobbs 2005 concluded that these differences in uptake were due
to improved coverage attained over the 12 months period of the
Hobbs 2005 study, compared to the Morgan 2002 study which
ran over six months. An excluded study (Wheeldon 1998), which
was also conducted in the primary care setting in England, invited
all patients aged 65 years and over for a 12-lead ECG to screen
for AF and reported an uptake rate of 85%. The uptake rate of
ECG screening reported in this study, which was excluded due to
the absence of a comparison group receiving routine care, differs
considerably from that of the systematic screening arm in Hobbs
2005, which achieved an uptake rate of 53%. These differences
provide an indication of the variability that can exist within and
between different screening strategies.
Another factor requiring consideration is the percentage of diag-
noses made outside of the actual screening programmes within the
intervention arm in Hobbs 2005. Of the 74 new cases of AF iden-
tified in the systematic group, 22 (30%) were diagnosed outside of
the screening programme over the 12 months of the study. For op-
portunistic screening, a greater proportion of the 75 newly iden-
tified cases were diagnosed outside of the screening programme
(44/75, 59%) than within it (31/75, 41%). When calculations
are based only on patients who received the screening interven-
tion, systematic screening has a detection rate of 2.2% compared
with 0.9% for opportunistic screening. This implies a detection
rate for those who did not participate in screening of 1% and 3%
for the systematic and opportunistic groups, respectively. The de-
tection rate in non-participants in the systematic arm is similar
to that observed in the control arm (both approximately 1%), a
figure which contrasts with the significantly higher detection rate
seen in non-participants in the opportunistic arm (approximately
3%). The reasons for these differences are unclear, but they do
have potential implications for service providers considering the
introduction of AF screening and for how such services should be
evaluated following their introduction.
Subgroup analysis of data from the single included study indi-
cate that the effectiveness of both screening interventions is dif-
ferent in men and women. When male and female subgroups are
analysed separately, both systematic and opportunistic screening
continue to show a significant effect on new case detection com-
pared with routine practice in men. No difference between either
systematic or opportunistic screening and routine practice is seen
in the subgroup of women. Possible reasons for this include dif-
ferences in the prevalence of AF in men and women, differences
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in the rate of uptake, or differences in the overall numbers in
each group, which would result in subgroups being underpowered
to detect significant effects. However this study included more
women than men in both intervention groups (1958 men com-
paredwith 2604women in systematic group; 1941men compared
with 2634 women in opportunistic group; 1880 men compared
with 2633 women in control group) so the female subgroup was
better powered to detect differences. However, though the study
included more women it was still underpowered to detect effect
sizes of the magnitude seen in the overall study within the sub-
group ofwomen.The rate of uptake of screeningwas higher among
men than women (57% versus 50% for systematic; 49% versus
41% for opportunistic), though more women agreed to have their
pulses taken in the opportunistic arm (71% versus 67%). It has
consistently been shown that there is a higher prevalence of AF in
men than in women (Gowd 2012) and this is borne out in the
baseline prevalences reported in this study (7.8% in males, 6.8%
in females). Therefore the differences in effect observed between
the subgroups of men and women could be due to a combination
of higher prevalence and greater rates of participation among men.
This finding may also have implications for the provision of AF
screening programmes.
Other factors that may affect the transferability of these results are
the direct patient costs associated with screening (which can affect
uptake) and the prevalence of undiagnosed AF. While the direct
costs to patients are low in a publicly funded screening programme,
the coverage achievable with opportunistic screening where GP
care is not provided free at the point of use may be lower than that
reported in the included study, and funding models that subsidise
GP care for a proportion of the population may also affect who
benefits from screening (McGregor 2006). Within the NHS, fi-
nancial incentives introduced since the completion of this study
through the Quality and Outcomes Framework (QoF), which en-
courage GPs to diagnose AF, may limit the effectiveness of screen-
ing compared to no screening since the prevalence of undiagnosed
AFmay be lower now than in 2003, when this research was carried
out. In addition, this type of incentive may prove more effective
in terms of identifying cases of AF than a screening programme,
or may alter the delivery and uptake of screening programmes.
These issues need to be taken into account when considering the
applicability of these results in a given healthcare setting.
The study that met the inclusion criteria for this review compared
systematic screening via an invitation to attend an ECG clinic and
opportunistic screening via pulse palpation during routine consul-
tations. However, there are a range of other strategies that could
be used to screen for the arrhythmia in a variety of settings. As no
studies comparing these to routine practice were identified, this
review is limited in terms of the screening interventions that could
be compared. Alternative screening strategies that have been de-
scribed in studies that were excluded include the use of self screen-
ing methods (Baxter 1998, Munschauer 1999), population based
screening programme using a national media campaign to invite
participants (Claes 2012), systematic screening where patients are
invited for pulse palpation rather than an ECG (Morgan 2002),
and opportunistic ECG recording (Caldwell 2012).
Quality of the evidence
There is a lack of studies comparing screening for AF to routine
practice. Only one eligible study was identified (Hobbs 2005),
which was judged to be of moderate quality.
Potential biases in the review process
A comprehensive search was carried out to identify RCTs, CBA
and ITS studies that compared screening for AF to routine prac-
tice in a general population of people aged over 40 years. Authors
of relevant published or ongoing studies were contacted to en-
quire about other studies in this area. Overall this search returned
19,936 citations which were inspected to identify relevant studies.
Only one cluster-RCT met the inclusion criteria, and the popula-
tion included in this study was aged 65 years and over. Given the
meticulous search that was conducted, the potential for publica-
tion bias is considered low. The input of a third author to settle
disagreements concerning inclusion of individual studies was not
required and data from the included study were cross-checked by
two authors (PM, CT).
Agreements and disagreements with other
studies or reviews
A recent review of strategies for the detection of AF (Harris 2012)
identified two studies (Morgan 2002; Hobbs 2005) examining
the effectiveness of screening. The conclusions are in line with
those of Hobbs 2005, recommending opportunistic screening in
the general population and highlighting that while a 12-lead ECG
remains the standard investigation, the cost-effectiveness of newer
technologies requires further research.
The overall rate of detection of new cases of AF in both interven-
tion groups and the control group in the Hobbs 2005 study was
approximately 1.6% and 1% respectively. Two studies that were
excluded due to the absence of a control arm in the study design
also reported the rate of detection of new cases of AF over the
course of the study. Morgan 2002 reported a new case detection
rate of 0.8% for systematic screening via an invitation to attend
nurse led pulse palpation and 0.4% for opportunistic pulse palpa-
tion; whereas Wheeldon 1998 reported a detection rate of 0.8%
for systematic screening via an invitation to undergo a 12-lead
ECG. Though these studies could not be included in this review,
they provide some context in relation to the level of variability that
exists between studies in this area.
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Implications for practice
Both systematic and opportunistic screening increase the rate of
detection of new AF cases compared with routine practice in peo-
ple over the age of 65 years in a primary care setting. In the absence
of additional data, caution needs to be exercised in drawing con-
clusions about the relative effectiveness of systematic and oppor-
tunistic screening. Based on the included study, both approaches
have a comparable effect on the overall AF diagnosis rate, with the
cost of systematic screening being significantly more than that of
opportunistic screening from the perspective of the health service
provider. The potential contribution of the educational element
of the intervention that occurred in both the systematic and op-
portunistic arms prior to screening should not be overlooked. This
may have influenced the number of new cases detected outside
of the screening programmes in both arms, something that was
particularly important in the opportunistic screening group where
59% of new diagnoses were made outside of the screening pro-
gramme itself. Systematic screening achieves a higher uptake rate
than that of opportunistic screening since about a third of people
who are found to have an irregular pulse when opportunistically
screened decline a confirmatory ECG test. This may pose ethical
issues with regard to treatment of patient for whom an irregular
pulse is recorded but ECG confirmation is absent. Based on the
available evidence, screening offered tomales ismore effective than
screening among females compared with routine practice. The
lack of studies investigating the effect of screening in other health
systems and younger age groups means that caution needs to be
exercised in relation to the transferability of these results beyond
the setting and population in which the study was conducted.
Implications for research
Two trials are ongoing that may provide additional data relevant
to this review question (NCT01291953;NCT01593553). Future
studies should examine the effect of using different types of ECG
technology and different readers, which may have important im-
plications for both the clinical and cost effectiveness of system-
atic and opportunistic screening. In addition, high quality studies
examining the effectiveness of alternative screening strategies (for
example opportunistic ECG, self screening, etc) would help ex-
pand the evidence base in this area. Further research is also needed
to investigate the effect of screening on clinical outcomes such
as stroke, and in particular the effectiveness of anticoagulation in
screen detected versus non-screen detected patients.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hobbs 2005
Methods Multi-centre cluster-randomised controlled trial involving 50 (computerised) primary
care centres across theWest Midlands, UK, over a 12 month period. Randomisation was
stratified by levels of deprivation (Townsend quartiles) and practice size. A subsidiary trial
was embedded in the intervention arm, comparing two different screening strategies.
Overall time period was from October 2001 to February 2003
Participants Male and female patients over 65 years of age attending general practices in the UK.
Age range was 65 - 98 years, average age of 73.5 years.
A random sample of 10,000 patients from the intervention group were allocated ran-
domly to either systematic or opportunistic screening. Randomisation was stratified ac-
cording to whether or not AF had been previously diagnosed in order to have an equal
prevalence of known AF on both arms.
A random sample of 5000 was selected from the control population. After sampling, lists
were returned to practices to remove those who had died, moved or were terminally ill.
These were replaced from a back-up list which had been randomised at the same time
as the initial list
Final number of participants in control arm = 4963 from 25 general practices
Final number of participants in intervention arms = 4933 for opportunistic screening
and 4933 for systematic screening from 25 general practices
Baseline AF prevalence in the control population higher than in the intervention popu-
lations (7.9% versus 6.9%)
Interventions Training:
Staff at primary care centres in the intervention arms were given training on the impor-
tance of AF detection, available treatment options, and were encouraged to consider op-
portunistic screening of patients. Staff at control centres were given no training. Practice
nurses received ECG training prior to starting ECG clinics
Systematic screening:
All patients in the systematic screening arm were sent an invitation to attend a screening
clinic along with an information sheet. Non-responders were sent a reminder
Opportunistic screening:
Patients in the opportunistic screening arm had their records flagged to encourage staff
to undertake pulse recordings during routine consultation. Patients who had an irregular
pulse were given an information sheet and invited to attend a screening clinic
Screening clinics:
Screening clinics were run by practice nurses, who took patient histories, checked radial
pulse rate and whether it was regular or irregular, and recorded a 12-lead ECG. The pa-
tient was then asked to complete a questionnaire on the acceptability of the intervention.
All 12-lead ECGs were sent to two cardiologists for reporting. If there was disagreement
over the diagnosis a third cardiologist decided. Patients were informed of the results
within two weeks
Outcomes Primary outcomes:
New cases of atrial fibrillation detected within the 12 month study period
28Effectiveness of systematic screening for the detection of atrial fibrillation (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Hobbs 2005 (Continued)
Incremental cost per case detected
Secondary outcomes:
Cost-effectiveness of screening in the UK
Community prevalence and incidence of AF
Acceptability of AF screening and patient uptake
Funding This research was funded by the NHS research and development health technology
assessment programme (No 96/22/11)
Notes Intention-to-treat analysis was performed, patients who already had a diagnosis of AF
excluded from the calculation of newly detected cases
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Probably done for control and intervention
groups “After stratification for practice size
and deprivation (based onTownsend score)
, we used MINITAB to select randomly
two equal size groups from those practices
within a particular stratum.We used a sim-
ulated value from a Bernoulli distribution,
comprising two values equally likely to oc-
cur, to determine which group became the
intervention arm (the other being the con-
trol arm)”
Also probably done for embedded trial
within the intervention arm: “We used
SPSS to allocate patients randomly from
this list to either systematic or opportunis-
tic screening to create two equal size groups
of patients within each stratum so that
each strategy (systematic or opportunistic
screening) had an equal chance of detecting
known, unknown, and suspected atrial fib-
rillation (n=4933). Which group then be-
came the systematic arm (the other being
opportunistic) was again decided by using a
simulated value from a Bernoulli distribu-
tion, comprising two values equally likely
to occur.”
Allocation concealment (selection bias) Unclear risk The authors state that “there was no delib-
erate concealment of allocation to the trial
arms...the trial statistician determined allo-
cation, which was implemented by the trial
coordinator”. However the clusters (GP
practices) were identified and recruited be-
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fore randomisation was conducted, so allo-
cation was concealed from the people pro-
viding permission for the cluster to be in-
cluded in the trial. Similarly, patients in
the intervention arm were identified and
randomly allocated into two groups before
it was known to anyone involved in the
trial which group would be allocated to
which treatment (opportunistic or system-
atic), since this was decided at the end of
the randomisation process using a simu-
lated value from a Bernoulli distribution,
comprising two values equally likely to oc-
cur. However since there was no deliberate
attempt to conceal allocation it is unclear
to what extent a risk of selection bias might
have arisen from practices in the interven-
tion arm knowing they were in the inter-
vention arm and not the control arm prior
to the recruitment of participants
Blinding of participants and personnel
(performance bias)
All outcomes
High risk It was not possible to blind patients, who
were notified by letter that they were being
offered the opportunity to participate in an
AF screening clinic or were encouraged to
have their pulse recorded during routine
consultation. Neither were primary care
physicians and healthcare staff blinded,
since the intervention arm received train-
ing where they were informed of the im-
portance of detecting AF and its treatment.
Practice nurses at screening clinics who
took the patients’ medical history, pulse
and ECG were probably not blinded to
whether the patient came from the system-
atic or opportunistic arm. Blinding is not
feasible in a situation where well informed
patients who need to decide whether of
not they want to avail of screening are a
key component of the systematic screen-
ing intervention. However since inability
to blind a study is not equal to a blinded
study, it is classified as high risk. Screening
clinics were used to test patients from each
group according to the same protocol and
with the aid of a 12-lead ECGmachine (Bi-
olog)
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Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Blinding was performed where possible;
cardiologists who interpreted the 12-lead
ECG reading in order to make a diagnosis
of AF were blinded as to the allocation of
the patient fromwhom the ECGwas taken
Incomplete outcome data (attrition bias)
All outcomes
Low risk After random sampling to identify partici-
pants from the cluster-randomised primary
care centres, general practices were con-
tacted to exclude people who had died,
moved away or were terminally ill. These
exclusions were randomly filled from a re-
serve list of 10% of the practice patients
which was randomised at the same time as
the original list. Immediately prior to send-
ing screening invitations or flagging notes,
the general practices were again contacted
to exclude people who had since died,
moved or were terminally ill and these ex-
clusions were not replaced, with the num-
bers in each arm reported. The primary
outcome was calculated taking the origi-
nal figure using an ITT approach. Patients
within each group who already had a diag-
nosis of AF were excluded from the calcu-
lation of the primary outcome (new cases
detected). This necessitated a review of pa-
tient record to identify those with a pre-ex-
isting diagnosis. Records for some people
in each of the groups were missing and are
reported for each group individually. Both
patients with AF and those with missing
notes were excluded from the calculation
of the rate of new cases detected
Selective reporting (reporting bias) Low risk All outcomes specified in the trial protocol
were reported
Other bias Unclear risk There is the potential for recruitment bias
and contamination in the study. Recruit-
ment bias could have been introduced at
the stage where general practitioners were
asked to exclude unsuitable patients from
the opportunistic and systematic screening
arms within the intervention group. Advice
was given to exclude those who had died,
moved away or were terminally ill from
both groups. People who were excluded at
this stage were replaced from a back-up
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list of patients that had been randomised
at the same time as the groups. No data
are provided about how many from each
group were replaced at this stage, nor is the
breakdown of the reasons for their exclu-
sion given. Immediately prior to the inter-
vention GPs were again asked to exclude
any patients who had died, moved away or
were terminally ill from both groups. Data
concerning exclusions at this stage are re-
ported and there was a considerable differ-
ence in the numbers excluded between the
two arms; 500 were excluded from the sys-
tematic screening arm (10% of the total)
and 195 (4% of the total). However the
individual reasons for exclusion from the
systematic screening arm are also reported
and only a small minority of these (9 peo-
ple, 0.2%of total) were deemed unsuitable,
as opposed to having died or moved away
(491people, 9.9% of total). An ITT anal-
ysis was performed that included patients
that were removed from the intervention
group at this stage in the calculation of the
primary outcome
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACTRN12612000406808 Ineligible study design - no control group. This is an ongoing non-randomised registered trial where
community pharmacists will screen members of the general public for atrial fibrillation using a com-
bination of a manual pulse check and a handheld single-lead ECG (using the AliveCor Heart Moni-
tor for iPhone). This will be a once off screening of approximately 5-10 minutes duration. Following
screening, the pharmacist will contact the participant’s GP via letter, stating the provisional diagnosis.
A cardiologist will review all of the single-lead ECG recordings to ensure the pharmacists interpretation
is correct. The GP will be further contacted by the research team if the diagnosis is other than reported
by the pharmacist. The screening trial will be conducted over a 6-month period
Baxter 1998 Ineligible study design - this was a pilot study of self screening for AF in an older population (age
range 55-75 years). No controls were used and irregular pulse readings were not confirmed using ECG.
Communication with corresponding author indicated that the study had not been continued further
following this publication
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Claes 2012 Ineligible study design - no control group. This report describes a study where “patients over 40
years were invited through different channels (TV, radio, journals, web site, posters, leaflets) for a free
screening in 69 hospitals allocated over Belgium during one week. After filling in a question on their
personal history of AF, they had to fill in a questionnaire about their CHAD2-score. Afterwards a one
channel ECGwas taken using a versatile Heart Scan Device (OmronHCG-801-E©) by a trained nurse
or a physician. If the ECG was positive for AF the patient was referred to their physician for follow-up.
” No control group receiving routine care was included or no time series data were recorded to examine
the effect of the intervention compared with no screening. 10,758 people over 40 years participated,
resulting in 167 new diagnoses of AF. When calculated on the basis of those who responded to the
media campaign the detection rate for new cases of AF is approximately 1.56%. It is not possible to
calculate the rate of detection based on the total number of people who received an invitation
DeRuijter 2008 Ineligible study design - this was a prospective cohort study to evaluate whether routinely performed
ECGs in older people from the general population have added value for cardiovascular risk management
beyond the information that is already available from their medical records
Ho 2004 Ineligible study design - no controls. In this study “500 subjects were drawn by two-stage random
sampling from 5,002 subjects aged 70 years and over living at home. Subjects were screened for atrial
fibrillation and left ventricular systolic dysfunction using electrocardiography and echocardiography.”
This was a prevalence study with no data on the effect of screening compared with routine care
Hoefman 2005 Ineligible population - participants in this study were consecutive patients presenting with unexplained
symptoms suggestive of arrhythmia
Johnson 2010 Ineligible study design - no controls. This conference abstract describes a study that employed a strategy
of random screening in a public venue (an inner city public market) to determine stroke risk. However
no controls were used and results were not compared to multiple time points pre and post-intervention.
No diagnoses of AF were made
Maeda 2004 Ineligible study design - this was an economic evaluation which modelled the clinical outcomes and
costs associated with a screening programme in Japan
Marek 2011 Ineligible study design - this a retrospective cohort study of large-scale electrocardiographic screening
of young adults
Morgan 2002 Ineligible study design - no controls. This was a randomised trial comparing two different screening
strategies. Patients were randomised either to nurse led screening or to prompted opportunistic case
finding. Irregular pulses found during opportunistic screening did not need to be confirmed by ECG.
The study was carried out over a 6-month period. Uptake in the systematic screening arm was 73%,
compared to 29% (for pulse palpation alone) in the opportunistic arm. The detection rate of new cases
of AF in the systematic arm was 0.8%, compared with 0.4% in the opportunistic arm
Munschauer 1999 Ineligible study design - this studywas designed to determine whether individuals taken from the general
community could be taught to find and classify the pulse of another as very irregular, implying AF, or
regular, implying normal sinus rhythm (NSR). No data on the effectiveness of a screening programme
compared to routine practice were reported
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(Continued)
Somerville 2000 Ineligible study design - this study compared different methods of identifying cases in general practice
using patients over 65 recruited from a general practice. 56% of invitees accepted an invitation for
testing (86/154) but no data were reported on the rate of detection of new cases. The study was not
designed to investigate the effect of screening compared with routine practice
Sudlow 1998 Ineligible study design - no controls. This study compares three methods of diagnosing AF in a sample
of 1235 over 65’s invited from 9 general practices in the UK. The three methods of screening used
were 1) checking for a digoxin prescription 2) pulse palpation and 3) limb lead ECG. Response rate
was 74% (916/1235). No data on rate of new diagnoses were reported
Wheeldon 1998 Ineligible study design - all patients over 65 years of age from a single primary care practice with 4 GPs
were invited to attend for a 12-lead ECG to detect AF. An uptake rate of 85% was achieved (1207/
1422). The overall detection rate of new cases of AF was approximately 0.4%
Wright 2007 Ineligible study design - no controls. This study randomised primary care centres to either implementing
AF or TIA guidelines. The type of AF testing that was associated with the AF guidelines was unclear
but effects on the rate of diagnosis of new cases of AF was reported. However there was no control arm
receiving routine care
Characteristics of ongoing studies [ordered by study ID]
NCT01291953
Trial name or title Effectiveness of Early Detection of Atrial Fibrillation (FAMDAP)
Methods Multi-centre cluster-randomised controlled trial. Primary care centre professionals will be randomised to
either the intervention group or a control group involving routine practice
Participants Men and women over 65 years of age who are attending a primary care centre for any reason. Patients with a
prior diagnosis of AF will be excluded. Anticipated enrolment of 12,870 participants
Interventions Opportunistic screening of people aged 65 year or more presenting at primary care services. Opportunistic
screening will involve pulse taking and requesting an ECG if an irregular pulse is found
Outcomes Primary outcome is the numbers of new diagnoses of AF using opportunistic screening versus routine practice
Starting date January 2011
Contact information Principal Investigator: Luis Angel Pérula de Torres, Andalusian Health Service, langel.perula.
sspa@juntadeandalucia.es
Notes Trial ongoing, protocol due to be submitted for publication. Estimated completion in late 2012
ClinicalTrials.gov identifier: NCT01593553
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NCT01593553
Trial name or title Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm
and Halland, Sweden
Methods Randomised controlled trial
Participants Men and women 75-76 years of age living in the region of Stockholm or Halland. Anticipated enrolment of
6500 participants
Interventions ECG screening for atrial fibrillation with intermittent ECG recording for 14 days. Introduction of anticoag-
ulants in the case of atrial fibrillation
Outcomes Reduced incidence of stroke among 75 year old subjects.
Starting date March 2012
Contact information Anna Hollander, RN LicMedSci +46-8-51778214 anna.hollander@karolinska.se
Notes Trial ongoing, estimated completion March 2019
ClinicalTrials.gov identifier: NCT01291953
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D A T A A N D A N A L Y S E S
Comparison 1. Detection of new cases of atrial fibrillation versus routine practice
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systematic Screening versus
Routine Practice
1 9075 Odds Ratio (M-H, Fixed, 95% CI) 1.57 [1.08, 2.26]
2 Opportunistic Screening versus
Routine Practice
1 9088 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [1.10, 2.29]
3 Gender Subgroups (Systematic) 1 9075 Odds Ratio (M-H, Fixed, 95% CI) 1.56 [1.08, 2.26]
3.1 Men 1 3838 Odds Ratio (M-H, Fixed, 95% CI) 2.68 [1.51, 4.76]
3.2 Women 1 5237 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.59, 1.62]
4 Age Subgroups (Systematic) 1 9075 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [1.09, 2.29]
4.1 Aged 65-74 years 1 5034 Odds Ratio (M-H, Fixed, 95% CI) 1.62 [0.90, 2.91]
4.2 Aged >74 years 1 4041 Odds Ratio (M-H, Fixed, 95% CI) 1.56 [0.97, 2.50]
5 Gender Subgroups
(Opportunistic)
1 9088 Odds Ratio (M-H, Fixed, 95% CI) 1.58 [1.10, 2.29]
5.1 Men 1 3821 Odds Ratio (M-H, Fixed, 95% CI) 2.33 [1.29, 4.19]
5.2 Women 1 5267 Odds Ratio (M-H, Fixed, 95% CI) 1.20 [0.74, 1.93]
6 Age Subgroups (Opportunistic) 1 9088 Odds Ratio (M-H, Fixed, 95% CI) 1.61 [1.12, 2.33]
6.1 Aged 65-74 years 1 5100 Odds Ratio (M-H, Fixed, 95% CI) 1.63 [0.91, 2.92]
6.2 Aged > 74 years 1 3988 Odds Ratio (M-H, Fixed, 95% CI) 1.60 [1.00, 2.57]
Comparison 2. Detection of new cases of atrial fibrillation versus other screening
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Systematic versus Opportunistic
Screening
1 9137 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.72, 1.37]
2 Gender Subgroups 1 9137 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.71, 1.36]
2.1 Men 1 3899 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.74, 1.79]
2.2 Women 1 5238 Odds Ratio (M-H, Fixed, 95% CI) 0.82 [0.50, 1.33]
3 Age Subgroups 1 9137 Odds Ratio (M-H, Fixed, 95% CI) 0.98 [0.71, 1.36]
3.1 Aged 65-74 years 1 5190 Odds Ratio (M-H, Fixed, 95% CI) 0.99 [0.60, 1.64]
3.2 Aged > 74 years 1 3947 Odds Ratio (M-H, Fixed, 95% CI) 0.97 [0.64, 1.48]
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Analysis 1.1. Comparison 1 Detection of new cases of atrial fibrillation versus routine practice, Outcome 1
Systematic Screening versus Routine Practice.
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 1 Detection of new cases of atrial fibrillation versus routine practice
Outcome: 1 Systematic Screening versus Routine Practice
Study or subgroup Systematic Screening Routine Practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hobbs 2005 74/4562 47/4513 100.0 % 1.57 [ 1.08, 2.26 ]
Total (95% CI) 4562 4513 100.0 % 1.57 [ 1.08, 2.26 ]
Total events: 74 (Systematic Screening), 47 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 2.39 (P = 0.017)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Routine Practice Favours Screening
Analysis 1.2. Comparison 1 Detection of new cases of atrial fibrillation versus routine practice, Outcome 2
Opportunistic Screening versus Routine Practice.
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 1 Detection of new cases of atrial fibrillation versus routine practice
Outcome: 2 Opportunistic Screening versus Routine Practice
Study or subgroup
Opportunistic
Screening Routine Practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hobbs 2005 75/4575 47/4513 100.0 % 1.58 [ 1.10, 2.29 ]
Total (95% CI) 4575 4513 100.0 % 1.58 [ 1.10, 2.29 ]
Total events: 75 (Opportunistic Screening), 47 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 2.46 (P = 0.014)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Routine Practice Favours Screening
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Analysis 1.3. Comparison 1 Detection of new cases of atrial fibrillation versus routine practice, Outcome 3
Gender Subgroups (Systematic).
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 1 Detection of new cases of atrial fibrillation versus routine practice
Outcome: 3 Gender Subgroups (Systematic)
Study or subgroup Systematic Screening Routine Practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Men
Hobbs 2005 44/1958 16/1880 34.4 % 2.68 [ 1.51, 4.76 ]
Subtotal (95% CI) 1958 1880 34.4 % 2.68 [ 1.51, 4.76 ]
Total events: 44 (Systematic Screening), 16 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 3.35 (P = 0.00080)
2 Women
Hobbs 2005 30/2604 31/2633 65.6 % 0.98 [ 0.59, 1.62 ]
Subtotal (95% CI) 2604 2633 65.6 % 0.98 [ 0.59, 1.62 ]
Total events: 30 (Systematic Screening), 31 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
Total (95% CI) 4562 4513 100.0 % 1.56 [ 1.08, 2.26 ]
Total events: 74 (Systematic Screening), 47 (Routine Practice)
Heterogeneity: Chi2 = 6.67, df = 1 (P = 0.01); I2 =85%
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Chi2 = 6.64, df = 1 (P = 0.01), I2 =85%
0.01 0.1 1 10 100
Favours Routine Practice Favours Screening
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Analysis 1.4. Comparison 1 Detection of new cases of atrial fibrillation versus routine practice, Outcome 4
Age Subgroups (Systematic).
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 1 Detection of new cases of atrial fibrillation versus routine practice
Outcome: 4 Age Subgroups (Systematic)
Study or subgroup Systematic Screening Routine Practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Aged 65-74 years
Hobbs 2005 30/2562 18/2472 39.2 % 1.62 [ 0.90, 2.91 ]
Subtotal (95% CI) 2562 2472 39.2 % 1.62 [ 0.90, 2.91 ]
Total events: 30 (Systematic Screening), 18 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
2 Aged >74 years
Hobbs 2005 44/2000 29/2041 60.8 % 1.56 [ 0.97, 2.50 ]
Subtotal (95% CI) 2000 2041 60.8 % 1.56 [ 0.97, 2.50 ]
Total events: 44 (Systematic Screening), 29 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 1.84 (P = 0.065)
Total (95% CI) 4562 4513 100.0 % 1.58 [ 1.09, 2.29 ]
Total events: 74 (Systematic Screening), 47 (Routine Practice)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.93), I2 =0.0%
0.01 0.1 1 10 100
Favours Routine Practice Favours Screening
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Analysis 1.5. Comparison 1 Detection of new cases of atrial fibrillation versus routine practice, Outcome 5
Gender Subgroups (Opportunistic).
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 1 Detection of new cases of atrial fibrillation versus routine practice
Outcome: 5 Gender Subgroups (Opportunistic)
Study or subgroup Opportunistic Routine Practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Men
Hobbs 2005 38/1941 16/1880 34.3 % 2.33 [ 1.29, 4.19 ]
Subtotal (95% CI) 1941 1880 34.3 % 2.33 [ 1.29, 4.19 ]
Total events: 38 (Opportunistic), 16 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 2.82 (P = 0.0049)
2 Women
Hobbs 2005 37/2634 31/2633 65.7 % 1.20 [ 0.74, 1.93 ]
Subtotal (95% CI) 2634 2633 65.7 % 1.20 [ 0.74, 1.93 ]
Total events: 37 (Opportunistic), 31 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.47)
Total (95% CI) 4575 4513 100.0 % 1.58 [ 1.10, 2.29 ]
Total events: 75 (Opportunistic), 47 (Routine Practice)
Heterogeneity: Chi2 = 2.96, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 2.45 (P = 0.014)
Test for subgroup differences: Chi2 = 2.95, df = 1 (P = 0.09), I2 =66%
0.01 0.1 1 10 100
Favours experimental Favours control
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Analysis 1.6. Comparison 1 Detection of new cases of atrial fibrillation versus routine practice, Outcome 6
Age Subgroups (Opportunistic).
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 1 Detection of new cases of atrial fibrillation versus routine practice
Outcome: 6 Age Subgroups (Opportunistic)
Study or subgroup Opportunistic Routine Practice Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Aged 65-74 years
Hobbs 2005 31/2628 18/2472 39.8 % 1.63 [ 0.91, 2.92 ]
Subtotal (95% CI) 2628 2472 39.8 % 1.63 [ 0.91, 2.92 ]
Total events: 31 (Opportunistic), 18 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 1.64 (P = 0.10)
2 Aged > 74 years
Hobbs 2005 44/1947 29/2041 60.2 % 1.60 [ 1.00, 2.57 ]
Subtotal (95% CI) 1947 2041 60.2 % 1.60 [ 1.00, 2.57 ]
Total events: 44 (Opportunistic), 29 (Routine Practice)
Heterogeneity: not applicable
Test for overall effect: Z = 1.96 (P = 0.050)
Total (95% CI) 4575 4513 100.0 % 1.61 [ 1.12, 2.33 ]
Total events: 75 (Opportunistic), 47 (Routine Practice)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.55 (P = 0.011)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.97), I2 =0.0%
0.01 0.1 1 10 100
Favours routine practice Favours screening
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Analysis 2.1. Comparison 2 Detection of new cases of atrial fibrillation versus other screening, Outcome 1
Systematic versus Opportunistic Screening.
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 2 Detection of new cases of atrial fibrillation versus other screening
Outcome: 1 Systematic versus Opportunistic Screening
Study or subgroup Systematic Opportunistic Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hobbs 2005 74/4562 75/4575 100.0 % 0.99 [ 0.72, 1.37 ]
Total (95% CI) 4562 4575 100.0 % 0.99 [ 0.72, 1.37 ]
Total events: 74 (Systematic), 75 (Opportunistic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.07 (P = 0.95)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours Opportunistic Favours Systematic
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Analysis 2.2. Comparison 2 Detection of new cases of atrial fibrillation versus other screening, Outcome 2
Gender Subgroups.
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 2 Detection of new cases of atrial fibrillation versus other screening
Outcome: 2 Gender Subgroups
Study or subgroup Systematic Opportunistic Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Men
Hobbs 2005 44/1958 38/1941 50.6 % 1.15 [ 0.74, 1.79 ]
Subtotal (95% CI) 1958 1941 50.6 % 1.15 [ 0.74, 1.79 ]
Total events: 44 (Systematic), 38 (Opportunistic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.63 (P = 0.53)
2 Women
Hobbs 2005 30/2604 37/2634 49.4 % 0.82 [ 0.50, 1.33 ]
Subtotal (95% CI) 2604 2634 49.4 % 0.82 [ 0.50, 1.33 ]
Total events: 30 (Systematic), 37 (Opportunistic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 4562 4575 100.0 % 0.99 [ 0.71, 1.36 ]
Total events: 74 (Systematic), 75 (Opportunistic)
Heterogeneity: Chi2 = 1.05, df = 1 (P = 0.31); I2 =5%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Chi2 = 1.05, df = 1 (P = 0.31), I2 =5%
0.5 0.7 1 1.5 2
Favours Opportunistic Favours Systematic
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Analysis 2.3. Comparison 2 Detection of new cases of atrial fibrillation versus other screening, Outcome 3
Age Subgroups.
Review: Effectiveness of systematic screening for the detection of atrial fibrillation
Comparison: 2 Detection of new cases of atrial fibrillation versus other screening
Outcome: 3 Age Subgroups
Study or subgroup Systematic Opportunistic Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Aged 65-74 years
Hobbs 2005 30/2562 31/2628 41.0 % 0.99 [ 0.60, 1.64 ]
Subtotal (95% CI) 2562 2628 41.0 % 0.99 [ 0.60, 1.64 ]
Total events: 30 (Systematic), 31 (Opportunistic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.98)
2 Aged > 74 years
Hobbs 2005 44/2000 44/1947 59.0 % 0.97 [ 0.64, 1.48 ]
Subtotal (95% CI) 2000 1947 59.0 % 0.97 [ 0.64, 1.48 ]
Total events: 44 (Systematic), 44 (Opportunistic)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 4562 4575 100.0 % 0.98 [ 0.71, 1.36 ]
Total events: 74 (Systematic), 75 (Opportunistic)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Chi2 = 0.00, df = 1 (P = 0.95), I2 =0.0%
0.5 0.7 1 1.5 2
Favours Opportunistic Favours Systematic
A D D I T I O N A L T A B L E S
Table 1. Number of new AF cases detected through screening versus routine practice
Gender Age Group Total
Men Women 65 - 74 75+
Systematic Screen-
ing
44/1958 30/2604 30/2562 44/2000 74/4562
Opportunistic
Screening
38/1941 37/2634 31/2628 44/1947 75/4575
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Table 1. Number of new AF cases detected through screening versus routine practice (Continued)
Routine Practice 16/1880 31/2633 18/2472 29/2041 47/4513
Data taken from Hobbs 2005 (reported in Fitzmaurice 2007)
Table 2. Uptake of screening
Group Systematic Screening Opportunistic Screening
All 53% 46%
Men 57% 49%
Women 50% 41%
Aged 65 - 74 61% 49%
Aged 75+ age 43% 42%
Rates of uptake of screening based on data reported in Hobbs 2005. Rate of uptake of opportunistic screening is based on those who
consented to have their pulse taken AND undergo an ECG if an irregular pulse was found.
Table 3. Prevalence data (by gender, age group)
Men Women
Total
Group 65 - 74 75 - 84 ≥ 85 65 - 74 75 - 84 ≥ 85
Baseline Prevalence
Control 74/1216 (6.1) 84/703 (11.9) 25/156 (16.0) 44/1378 (3.2) 106/1050 (10.
1)
56/420 (13.3) 389/4923 (7.
9)
Opportunistic 70/1304 (5.4) 63/650 (9.7) 24/148 (16.2) 48/1448 (3.3) 91/1005 (9.1) 44/375 (11.7) 340/4930 (6.
9)
Systematic 69/1318 (5.2) 67/647 (10.4) 15/154 (9.7) 68/1391 (4.9) 70/1022 (6.8) 50/396 (12.6) 339/4928 (6.
9)
12 month prevalence
Control 81/1213 (6.7) 91/699 (13.0) 27/151 (17.9) 55/1377 (4.0) 122/1044 (11.
7)
60/418 (14.4) 436/4902 (8.
9)
Opportunistic 90/1303 (6.9) 77/647 (11.9) 28/148 (18.9) 59/1443 (4.1) 109/1001 (10.
9)
52/373 (13.9) 415/4915 (8.
4)
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Table 3. Prevalence data (by gender, age group) (Continued)
Systematic 90/1312 (6.9) 82/643 (12.8) 23/154 (14.9) 77/1387 (5.6) 88/1012 (8.7) 53/398 (13.5) 413/4906 (8.
4)
Data taken from Hobbs 2005 (reported in Fitzmaurice 2007), Figures are number (percentages)
A P P E N D I C E S
Appendix 1. Search strategies - RCT
CENTRAL
#1 MeSH descriptor Mass Screening, this term only
#2 (screen*)
#3 MeSH descriptor Diagnosis, this term only
#4 MeSH descriptor Diagnostic Techniques and Procedures, this term only
#5 diagnos*
#6 (identif*)
#7 test*
#8 (prevalence)
#9 (incidence*)
#10 ((systemat* or opportunist* or target* or population or mass) near/2 assess*)
#11 MeSH descriptor Electrocardiography, this term only
#12 MeSH descriptor Electrocardiography, Ambulatory, this term only
#13 (electrocardiogram*)
#14 (electrocardiograph*)
#15 (ecg)
#16 (ekg)
#17 (holter)
#18 (event monitor*)
#19 MeSH descriptor Pulse, this term only
#20 (pulse near/3 test)
#21 (pulse near/3 tests)
#22 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16
OR #17 OR #18 OR #19 OR #20 OR #21)
#23 MeSH descriptor Atrial Fibrillation, this term only
#24 atrial fibrillation*
#25 (auricular fibrillation*)
#26 (atrium fibrillation*)
#27 (af )
#28 (a-fib)
#29 MeSH descriptor Atrial Flutter, this term only
#30 atrial flutter*
#31 (auricular flutter*)
#32 (#23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31)
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#33 (#22 AND #32)
MEDLINE
1 Mass Screening/ (72995)
2 screen*.tw. (363165)
3 Diagnosis/ (16201)
4 “Diagnostic Techniques and Procedures”/ (1840)
5 diagnos*.tw. (1357269)
6 identif*.tw. (1481939)
7 test*.tw. (1765452)
8 prevalence.tw. (294233)
9 incidence*.tw. (429563)
10 ((systemat* or opportunist* or target* or population or mass) adj2 assess*).tw. (6956)
11 Electrocardiography/ (154517)
12 Electrocardiography, Ambulatory/ (8229)
13 electrocardiogram*.tw. (29533)
14 electrocardiograph*.tw. (33936)
15 ecg.tw. (40730)
16 ekg.tw. (2117)
17 holter.tw. (7374)
18 event monitor*.tw. (603)
19 or/1-18 (4696543)
20 Atrial Fibrillation/ (28648)
21 atrial fibrillation*.tw. (29152)
22 auricular fibrillation*.tw. (740)
23 atrium fibrillation*.tw. (7)
24 af.tw. (15627)
25 a-fib.tw. (29)
26 Atrial Flutter/ (4663)
27 atrial flutter*.tw. (3879)
28 auricular flutter*.tw. (213)
29 or/20-28 (46988)
30 Pulse/ (15989)
31 (pulse adj3 test).tw. (633)
32 (pulse adj3 tests).tw. (94)
33 19 or 30 or 31 or 32 (4707679)
34 29 and 33 (22662)
35 randomized controlled trial.pt. (321630)
36 controlled clinical trial.pt. (83679)
37 randomized.ab. (226659)
38 placebo.ab. (129223)
39 clinical trials as topic.sh. (158452)
40 randomly.ab. (163835)
41 trial.ti. (97314)
42 35 or 36 or 37 or 38 or 39 or 40 or 41 (746444)
43 exp animals/ not humans.sh. (3683920)
44 42 not 43 (688202)
45 34 and 44 (2438)
EMBASE
1 mass screening/ (45098)
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2 screen*.tw. (481715)
3 diagnostic procedure/ (68098)
4 diagnosis/ (991556)
5 diagnos*.tw. (1978130)
6 ((systemat* or opportunist* or target* or population or mass) adj2 (assess* or test*)).tw. (17875)
7 identif*.tw. (1871499)
8 test*.tw. (2435524)
9 prevalence.tw. (385646)
10 incidence*.tw. (621772)
11 electrocardiography/ (126772)
12 electrocardiogram*.tw. (41746)
13 electrocardiograph*.tw. (47763)
14 ecg.tw. (70264)
15 ekg.tw. (3746)
16 holter.tw. (10268)
17 event monitor*.tw. (849)
18 (pulse adj3 test*).tw. (1412)
19 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 (6827758)
20 heart atrium fibrillation/ (60141)
21 atrial fibrillation.tw. (44810)
22 auricular fibrillation*.tw. (1890)
23 atrium fibrillation.tw. (31)
24 af.tw. (26527)
25 a-fib.tw. (88)
26 atrial flutter*.tw. (5705)
27 auricular flutter*.tw. (493)
28 or/20-27 (81706)
29 random$.tw. (711679)
30 factorial$.tw. (18953)
31 crossover$.tw. (42881)
32 cross over$.tw. (19756)
33 cross-over$.tw. (19756)
34 placebo$.tw. (176052)
35 (doubl$ adj blind$).tw. (132159)
36 (singl$ adj blind$).tw. (11978)
37 assign$.tw. (199920)
38 allocat$.tw. (67235)
39 volunteer$.tw. (161161)
40 crossover procedure/ (32434)
41 double blind procedure/ (108197)
42 randomized controlled trial/ (301358)
43 single blind procedure/ (14951)
44 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 (1197077)
45 (animal/ or nonhuman/) not human/ (4367025)
46 44 not 45 (1055312)
47 19 and 28 and 46 (3896)
48Effectiveness of systematic screening for the detection of atrial fibrillation (Review)
Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 2. Search strategies - ITS and CBA
MEDLINE
1 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or complex or DESIGN$ or doctor? or educational
or family doctor? or family physician? or family practitioner? or financial or GP or general practice? or hospital? or impact? or improv$
or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or multi-disciplin$ or
multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies or pharmacist? or pharmacy
or physician? or practitioner? or prescrib$ or prescription? or primary care or professional$ or provider? or regulatory or regulatory or
tailor$ or target$ or team$ or usual care)).ab. (116218)
2 (pre-intervention? or preintervention? or “pre intervention?” or post-intervention? or postintervention? or “post intervention?”).ti,ab.
(6563)
3 (hospital$ or patient?).hw. and (study or studies or care or health$ or practitioner? or provider? or physician? or nurse? or nursing or
doctor?).ti,hw. (638507)
4 demonstration project?.ti,ab. (1693)
5 (pre-post or “pre test$” or pretest$ or posttest$ or “post test$” or (pre adj5 post)).ti,ab. (48254)
6 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab. (436)
7 trial.ti. or ((study adj3 aim?) or “our study”).ab. (456696)
8 (before adj10 (after or during)).ti,ab. (299259)
9 (“quasi-experiment$” or quasiexperiment$ or “quasi random$” or quasirandom$ or “quasi control$” or quasicontrol$ or ((quasi$ or
experimental) adj3 (method$ or study or trial or design$))).ti,ab,hw. (79229)
10 (“time series” adj2 interrupt$).ti,ab,hw. (628)
11 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month$ or
hour? or day? or “more than”)).ab. (6325)
12 pilot.ti. (29638)
13 Pilot projects/ (69467)
14 (clinical trial or controlled clinical trial or multicenter study).pt. (572420)
15 (multicentre or multicenter or multi-centre or multi-center).ti. (22521)
16 random$.ti,ab. or controlled.ti. (582515)
17 (control adj3 (area or cohort? or compare? or condition or design or group? or intervention? or participant? or study)).ab. not
(controlled clinical trial or randomized controlled trial).pt. (320953)
18 “comment on”.cm. or review.ti,pt. or randomized controlled trial.pt. (2511343)
19 review.ti. (198703)
20 (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?).ti. (1214214)
21 exp animals/ not humans.sh. (3683920)
22 (animal$ not human$).sh,hw. (3590857)
23 *experimental design/ or *pilot study/ or quasi experimental study/ (17650)
24 (“quasi-experiment$” or quasiexperiment$ or “quasi random$” or quasirandom$ or “quasi control$” or quasicontrol$ or ((quasi$
or experimental) adj3 (method$ or study or trial or design$))).ti,ab. (79229)
25 (“time series” adj2 interrupt$).ti,ab. (628)
26 (or/1-17) not (or/18,20-21) (1712146)
27 (or/1-8,11-12,15-16,23-25) not (or/19,22) (1733779)
28 Mass Screening/ (72995)
29 screen*.tw. (363165)
30 Diagnosis/ (16201)
31 “Diagnostic Techniques and Procedures”/ (1840)
32 diagnos*.tw. (1357269)
33 identif*.tw. (1481939)
34 test*.tw. (1765452)
35 prevalence.tw. (294233)
36 incidence*.tw. (429563)
37 ((systemat* or opportunist* or target* or population or mass) adj2 assess*).tw. (6956)
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38 Electrocardiography/ (154517)
39 Electrocardiography, Ambulatory/ (8229)
40 electrocardiogram*.tw. (29533)
41 electrocardiograph*.tw. (33936)
42 ecg.tw. (40730)
43 ekg.tw. (2117)
44 holter.tw. (7374)
45 event monitor*.tw. (603)
46 or/28-45 (4696543)
47 Atrial Fibrillation/ (28648)
48 atrial fibrillation*.tw. (29152)
49 auricular fibrillation*.tw. (740)
50 atrium fibrillation*.tw. (7)
51 af.tw. (15627)
52 a-fib.tw. (29)
53 Atrial Flutter/ (4663)
54 atrial flutter*.tw. (3879)
55 auricular flutter*.tw. (213)
56 or/47-55 (46988)
57 Pulse/ (15989)
58 (pulse adj3 test).tw. (633)
59 (pulse adj3 tests).tw. (94)
60 46 or 57 or 58 or 59 (4707679)
61 56 and 60 (22662)
62 27 and 61 (4762)
EMBASE
1 intervention?.ti. or (intervention? adj6 (clinician? or collaborat$ or community or complex or DESIGN$ or doctor? or educational
or family doctor? or family physician? or family practitioner? or financial or GP or general practice? or hospital? or impact? or improv$
or individuali?e? or individuali?ing or interdisciplin$ or multicomponent or multi-component or multidisciplin$ or multi-disciplin$ or
multifacet$ or multi-facet$ or multimodal$ or multi-modal$ or personali?e? or personali?ing or pharmacies or pharmacist? or pharmacy
or physician? or practitioner? or prescrib$ or prescription? or primary care or professional$ or provider? or regulatory or regulatory or
tailor$ or target$ or team$ or usual care)).ab. (155670)
2 (pre-intervention? or preintervention? or “pre intervention?” or post-intervention? or postintervention? or “post intervention?”).ti,ab.
(8765)
3 (hospital$ or patient?).hw. and (study or studies or care or health$ or practitioner? or provider? or physician? or nurse? or nursing or
doctor?).ti,hw. (1314181)
4 demonstration project?.ti,ab. (2139)
5 (pre-post or “pre test$” or pretest$ or posttest$ or “post test$” or (pre adj5 post)).ti,ab. (70783)
6 (pre-workshop or post-workshop or (before adj3 workshop) or (after adj3 workshop)).ti,ab. (590)
7 trial.ti. or ((study adj3 aim?) or “our study”).ab. (636849)
8 (before adj10 (after or during)).ti,ab. (406770)
9 (“quasi-experiment$” or quasiexperiment$ or “quasi random$” or quasirandom$ or “quasi control$” or quasicontrol$ or ((quasi$ or
experimental) adj3 (method$ or study or trial or design$))).ti,ab,hw. (129464)
10 (“time series” adj2 interrupt$).ti,ab,hw. (796)
11 (time points adj3 (over or multiple or three or four or five or six or seven or eight or nine or ten or eleven or twelve or month$ or
hour? or day? or “more than”)).ab. (8452)
12 pilot.ti. (39826)
13 Pilot projects/ (52429)
14 (clinical trial or controlled clinical trial or multicenter study).pt. (0)
15 (multicentre or multicenter or multi-centre or multi-center).ti. (30589)
16 random$.ti,ab. or controlled.ti. (762754)
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17 (control adj3 (area or cohort? or compare? or condition or design or group? or intervention? or participant? or study)).ab. not
(controlled clinical trial or randomized controlled trial).pt. (504013)
18 “comment on”.cm. or review.ti,pt. or randomized controlled trial.pt. (1930931)
19 review.ti. (265182)
20 (rat or rats or cow or cows or chicken? or horse or horses or mice or mouse or bovine or animal?).ti. (1527399)
21 exp animals/ not humans.sh. (1681155)
22 (animal$ not human$).sh,hw. (3642616)
23 *experimental design/ or *pilot study/ or quasi experimental study/ (4322)
24 (“quasi-experiment$” or quasiexperiment$ or “quasi random$” or quasirandom$ or “quasi control$” or quasicontrol$ or ((quasi$
or experimental) adj3 (method$ or study or trial or design$))).ti,ab. (111602)
25 (“time series” adj2 interrupt$).ti,ab. (796)
26 (or/1-17) not (or/18,20-21) (2869531)
27 (or/1-8,11-12,15-16,23-25) not (or/19,22) (2707103)
28 mass screening/ (45098)
29 screen*.tw. (481715)
30 diagnostic procedure/ (68098)
31 diagnosis/ (991556)
32 diagnos*.tw. (1978130)
33 ((systemat* or opportunist* or target* or population or mass) adj2 (assess* or test*)).tw. (17875)
34 identif*.tw. (1871499)
35 test*.tw. (2435524)
36 prevalence.tw. (385646)
37 incidence*.tw. (621772)
38 electrocardiography/ (126772)
39 electrocardiogram*.tw. (41746)
40 electrocardiograph*.tw. (47763)
41 ecg.tw. (70264)
42 ekg.tw. (3746)
43 holter.tw. (10268)
44 event monitor*.tw. (849)
45 (pulse adj3 test*).tw. (1412)
46 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 (6827758)
47 heart atrium fibrillation/ (60141)
48 atrial fibrillation*.tw. (44880)
49 auricular fibrillation*.tw. (1890)
50 atrium fibrillation*.tw. (31)
51 af.tw. (26527)
52 a-fib.tw. (88)
53 atrial flutter*.tw. (5705)
54 auricular flutter*.tw. (493)
55 or/47-54 (81720)
56 27 and 46 and 55 (10898)
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Appendix 3. Searching other resources
Source Search Terms
ACC “atrial fibrillation”
Australia New Zealand Clinical Trials Registry
Brazilian Clinical Trials Registry
Chinese Clinical Trials Registry
Clinical Trials Registry India
Clinical Trials Registry of the University Medical Center Freiburg
ClinicalTrials.gov
EHRA
EU Clinical Trials Register
European Stroke Conference
Eurostroke
German Clinical Trials Register
Iranian Registry of Controlled Trials
ISRCTN Registry
Japanese NIPH Clinical Trials
Korean Clinical Research Information Service
Nederlands Trial Register
Pan African Clinical Trials Registry
Sri Lanka Clinical Trials Registry
Stroke Trials Directory
UMIN-CTR (Japan)
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(Continued)
CINAHL “atrial fibrillation” and “screening” [abstract]
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol included DARE and ISI Web Of Science with conference proceedings in the list of databases that were to be searched.
Given the high volume of results returned from MEDLINE, EMBASE and CENTRAL, these two databases were not included in the
search.
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Medical Subject Headings (MeSH)
∗Asymptomatic Diseases; Atrial Fibrillation [∗diagnosis]; Electrocardiography; Mass Screening [∗methods]; Palpation [methods]; Pulse
[methods]; Randomized Controlled Trials as Topic
MeSH check words
Aged; Female; Humans; Male
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